Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 32963. Отображено 100.
05-01-2012 дата публикации

Modulators of cytokine mediated signalling pathways and integrin alphavbeta3 receptor antagonists for combination therapy

Номер: US20120003229A1
Принадлежит: Individual

The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin αvβ3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin αvβ3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.

Подробнее
05-01-2012 дата публикации

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Номер: US20120004206A1

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Подробнее
05-01-2012 дата публикации

NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE

Номер: US20120004213A1
Принадлежит: Forest Laboratories Holdings Ltd

The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

Подробнее
05-01-2012 дата публикации

Modulators of atp-binding cassette transporters

Номер: US20120004216A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including CF Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Подробнее
12-01-2012 дата публикации

Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials

Номер: US20120010187A1

The invention provides FIG. 1 novel antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit antibacterial and antiparasitic action against a wide range of human pathogens. The new classes of compounds show extended action against Gram positive bacteria including MRSA drug resistant pathogens. In the Gram-positive organisms, they specifically target and functionally inhibit microbial attachment to surfaces and biofilm formation. In Gram-negative bacteria, including enteroaggregative E. coli strains, these compounds function as pilicides by inhibiting the assembly of pilin subunits into adhesive filaments. Several of these compounds show potent antimicrobial action against Gram positive bacteria, perhaps involving novel targets. Many of the benzothiophene derivatives exhibit antimicrobial activity in the low micrograms per ml range and in blocking biofilm formation in the nanomolar range; ranges considered are well within the range of utility as therapeutics.

Подробнее
19-01-2012 дата публикации

Taspase1 inhibitors and their uses

Номер: US20120015990A1
Автор: Emily Cheng, James Hsieh
Принадлежит: Washington University in St Louis WUSTL

Provided herein are small molecule inhibitors of Taspase1 and methods of using the small molecule inhibitors of Taspase1 to treat neoplasm in subjects in need thereof.

Подробнее
26-01-2012 дата публикации

Thiazole and oxazole-substituted arylamides as p2x3 and p2x2/3 antagonists

Номер: US20120022067A1
Принадлежит: Individual

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R 1 is a group of formula A or formula B, and X, R 2 , R 3 , R 4 , R 5 , R 6 , R a and R b are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist and methods of making the subject compounds.

Подробнее
26-01-2012 дата публикации

Derivatives of n-(arylamino)sulfonamides as inhibitors of mek

Номер: US20120022076A1
Принадлежит: Individual

This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

Подробнее
02-02-2012 дата публикации

3-biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide

Номер: US20120028804A1

The present invention relates to novel 3-biphenyl-substituted, 3-substituted 4-ketolactams and -lactones of the formula (I) in which A, B, Q, G, W, X, Y and Z are as defined in the disclosure, to processes for their preparation, and to their use as pesticides and/or microbicides and/or herbicides.

Подробнее
16-02-2012 дата публикации

Substituted acylguanidine derivatives (as amended)

Номер: US20120041036A1
Принадлежит: Astellas Pharma Inc

An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT 5A receptor modulating action. It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT 5A receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.

Подробнее
23-02-2012 дата публикации

Diacylethylenediamine compound

Номер: US20120046292A1
Принадлежит: Astellas Pharma Inc

[Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

Подробнее
22-03-2012 дата публикации

Estrogen receptor modulators and uses thereof

Номер: US20120071535A1
Принадлежит: Aragon Pharmaceuticals Inc

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Подробнее
12-04-2012 дата публикации

Five-membered heterocycles useful as serine protease inhibitors

Номер: US20120088758A1
Принадлежит: Bristol Myers Squibb Co

The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R 3 , R 4 , R 6 , R 11 , X 1 , X 2 , and X 3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

Подробнее
03-05-2012 дата публикации

Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators

Номер: US20120108571A1
Принадлежит: Individual

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Подробнее
03-05-2012 дата публикации

Nitrogen-containing aromatic heterocyclyl compound

Номер: US20120108639A1
Принадлежит: Daiichi Sankyo Co Ltd

The present invention provides a compound having excellent regulating action on blood lipid level that is represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein, in one embodiment, A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R 1 represents COOH; each R 2 represents an alkyl; each R 3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R 4 , R 5 , R 6 , and R 7 represents H, an alkyl; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B 1 and B 2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.

Подробнее
03-05-2012 дата публикации

Rubber crawler

Номер: US20120108738A1
Автор: Yoshikazu Tanimoto
Принадлежит: Bridgestone Corp

The present invention provides a rubber crawler with high durability by using the rubber composition, wherein said rubber composition exhibits enhanced adherence between rubber and metal reinforcing material, such as steel cord and the like, particularly adherence after heat aging and under high humidity, without using vulcanizing retarder, such as CTP, which has possibility of generating problems, such as blooming and lowering rubber physical properties after vulcanization; using vulcanization accelerator having the adequate vulcanization retarding effect exerting excellent working ability; lowering rubber scorching as much as possible. The rubber crawler of the present invention comprises a rubber composition as the treatment rubber thereof, which comprises in the amount of 0.1 to 10 parts by weight of sulfenamide-containing vulcanization accelerator, 0.03 to 3 parts by weight of cobalt-containing composition as the equivalent amount of cobalt and 0.3 to 10 parts by weight of sulfur, relative to 100 parts by weight of rubber component.

Подробнее
10-05-2012 дата публикации

N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation

Номер: US20120115915A1
Принадлежит: Harvard College

Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.

Подробнее
17-05-2012 дата публикации

Compounds, Compositions and Methods for Modulating Uric Acid Levels

Номер: US20120122780A1
Принадлежит: Ardea Biociences Inc

Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

Подробнее
17-05-2012 дата публикации

Libraries of n-substituted-n-phenylethylsulfonamides for drug discovery

Номер: US20120122920A1

New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to N-substituted-N-phenylethylsulfonamides libraries which can be used in the search for, and identification of, new lead compounds that could modulate the functional activity of a biological target.

Подробнее
24-05-2012 дата публикации

Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor

Номер: US20120129870A1
Принадлежит: Janssen Pharmaceutica NV

The present invention is directed to piperidinyl and piperazinyl derivatives of formula (II) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor.

Подробнее
07-06-2012 дата публикации

Microbiocidal heterocycles

Номер: US20120142700A1
Принадлежит: SYNGENTA CROP PROTECTION LLC

The present invention relates to heterocyclic compounds of formula (I) which have microbiocidal activity, in particular fungicidal activity, as well as methods of using the compounds of formula (I) to control microbes.

Подробнее
21-06-2012 дата публикации

Antibiotic compounds

Номер: US20120156295A1
Принадлежит: Piramal Healthcare Ltd

Purified compounds of formula I are described. Compounds include all stereoisomeric forms and all tautomeric forms of the compounds of formula I and pharmaceutically acceptable salts and derivatives. Processes for the production of the antibacterial compounds by fermentation of the microorganism belonging to Streptomyces species (PM0626271/MTCC 5447) and to pharmaceutical compositions containing one or more of the novel compounds as active ingredient and their use in medicines for treatment and prevention of diseases caused by bacterial infections are described.

Подробнее
21-06-2012 дата публикации

Phosphorous derivatives as chemokine receptor modulators

Номер: US20120157413A1
Принадлежит: Allergan Inc

The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

Подробнее
12-07-2012 дата публикации

Rho kinase inhibitors

Номер: US20120178752A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Подробнее
09-08-2012 дата публикации

Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents

Номер: US20120202857A1
Принадлежит: FerroKin BioScience Inc

Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Подробнее
23-08-2012 дата публикации

Viral polymerase inhibitors

Номер: US20120214783A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of formula I: wherein X, R 2 , R 3 , R 3a , R 3b , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

Подробнее
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214785A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
23-08-2012 дата публикации

Heteroaryls and uses thereof

Номер: US20120214794A1
Принадлежит: Millennium Pharmaceuticals Inc

This invention provides compounds of formula I-A or I-B: wherein HY, G 1 , G 2 , R 2 , R 12 , W 1 , W 2 , n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Подробнее
30-08-2012 дата публикации

Guanidine-containing compounds useful as muscarinic receptor antagonists

Номер: US20120219509A1
Принадлежит: Theravance Inc

The invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R 1-3 , R 5-7 , a, X, Y, Y′, Y″, and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.

Подробнее
04-10-2012 дата публикации

Thiazole derivatives for the treatment of diseases such as cancer

Номер: US20120252759A1
Принадлежит: Merck Patent GmBH

Compounds of the formula Ia and Ib, in which R 1 , R 1′ , R 2 , R 3 , R 5 , R 6 and R 7 have the meanings indicated in claim 1 , are kinase inhibitors and can be employed, inter alia, for the treatment of tumours.

Подробнее
01-11-2012 дата публикации

Using squaraine dyes as near infrared fluorescent sensors for protein detection

Номер: US20120276642A1
Автор: Yi Pang
Принадлежит: Individual

Squaraine dyes are used to detect the presence of protein in a test sample, which is a substance that may contain protein. A squarine dye is placed in water, and in some instances joined with an aggregation agent, to create an aqueous dye solution. That dye solution is joined with a test sample. When the dye solution is joined with the test sample and the resultant test solution is excited by the application of photons, a resulting fluorescence or absence thereof reveals if protein was present in the test sample.

Подробнее
01-11-2012 дата публикации

Novel heterocyclic acrylamides and their use as pharmaceuticals

Номер: US20120277207A1
Принадлежит: FAB PHARMA Sas

The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.

Подробнее
10-01-2013 дата публикации

Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same

Номер: US20130011788A1
Принадлежит: International Business Machines Corp

The present invention relates to a fluorine-free photoacid generator (PAG) and a photoresist composition containing the same. The PAG is characterized by the presence of an onium cationic component and a fluorine-free fused ring heteroaromatic sulfonate anionic component containing one or more electron withdrawing substituents. The onium cationic component of the PAG is preferably a sulfonium or an iodonium cation. The photoresist composition further contains an acid sensitive imaging polymer. The photoresist composition is especially useful for forming material patterns on a semiconductor substrate using 193 nm (ArF) lithography.

Подробнее
10-01-2013 дата публикации

Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same

Номер: US20130011793A1
Принадлежит: International Business Machines Corp

The present invention relates to a fluorine-free photoacid generator (PAG) and a photoresist composition containing the same. The PAG is characterized by the presence of an onium cationic component and a fluorine-free fused ring heteroaromatic sulfonate anionic component containing one or more electron withdrawing substituents. The onium cationic component of the PAG is preferably a sulfonium or an iodonium cation. The photoresist composition further contains an acid sensitive imaging polymer. The photoresist composition is especially useful for forming material patterns on a semiconductor substrate using 193 nm (ArF) lithography.

Подробнее
10-01-2013 дата публикации

Novel Heterocyclic Alkanol Derivatives

Номер: US20130012390A1
Принадлежит: Beyer Intellectual Property GmbH

The present invention relates to novel heterocyclic alkanol derivatives, to processes for preparing these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.

Подробнее
24-01-2013 дата публикации

Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disorders as agonists of g-protein coupled receptor 43 (gpr43)

Номер: US20130023539A1
Принадлежит: Euroscreen SA

The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.

Подробнее
07-02-2013 дата публикации

Pyrrolysine analogs

Номер: US20130035478A1
Принадлежит: Ohio State University

Several different pyrrolysine analogs are disclosed in this application. Those analogs have distinct chemical and biophysical properties. Some analogs are useful in chemical ligation applications. Methods of making and using are also disclosed.

Подробнее
14-02-2013 дата публикации

Cosmetic Or Dermatological Preparations With A Content Of One Or More Thiazole Derivates

Номер: US20130039870A1
Принадлежит: Beiersdorf AG

Cosmetic or dermatological preparations having an effective content of one or more thiazoles of the general formula

Подробнее
14-02-2013 дата публикации

Therapeutic agent and preventative agent for alzheimer's disease

Номер: US20130041158A1
Принадлежит: TORAY INDUSTRIES INC

A therapeutic agent or prophylactic agent for Alzheimer's disease has an effect to inhibit or delay the progress of Alzheimer's disease and exhibits a long-lasting therapeutic effect on Alzheimer's disease even when used for a long period of time. The therapeutic agent or prophylactic agent for Alzheimer's disease includes as an effective ingredient a cyclohexane derivative exemplified by the formula below, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

Подробнее
21-03-2013 дата публикации

Inhibitors of Ion Channels

Номер: US20130072471A1
Принадлежит:

Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel. 2. The compound of claim 1 , with the proviso that the compound of formula (I) is not one of the following compounds:N-(5-methyl-3-isoxazolyl)-3-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]-benzamide;3-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]-N-1,3,4-thiadiazol-2-yl-benzamide;N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-(4-morpholinylcarbonyl)-benzenesulfonamide;1-[3-[[[5-(1,1-dimethylethyl)-4-methyl-2-thiazolyl]amino]sulfonyl]benzoyl]piperidine;N-(5-methyl-1,3,4-thiadiazol-2-yl)-3-(4-morpholinylcarbonyl)-benzenesulfonamide; andN-methyl-4-[[(1-methyl-1H-pyrazol-3-yl)amino]sulfonyl]-benzamide.3. The compound according to claim 2 , or a pharmaceutically acceptable salt claim 2 , wherein{'sup': '5', 'sub': 1', '10', '3', '8, 'Ris a member selected from (C-C)alkyl and (C-C)cycloalkyl,'}{'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'wherein each is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen, cyano, hydroxy, hydroxy(C-C)alkyl, hydroxy(C-C)alkoxy, (C-C)alkyl, halo(C-C)alkyl, (C-C)alkoxy, halo(C-C)alkoxy and phenyl.'}4. The compound according to claim 3 , or a pharmaceutically acceptable salt claim 3 , wherein Ris a member selected from (C-C)alkyl claim 3 , hydroxy(C-C ...

Подробнее
28-03-2013 дата публикации

AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES

Номер: US20130078186A1

The present invention relates to compounds suitable as modulators of protein misfolding and/or protein aggregation. The compounds are particularly suitable as inhibitors of amyloid aggregate formation and/or modulators of amyloid surface properties, and/or as activators of degradation or reduction of amyloid aggregates. 2. The compound of claim 1 , which does not comprise a —COOH group.4. The compound of claim 1 , wherein Y is phenyl claim 1 , pyridyl such as pyrid-1-yl claim 1 , pyrid-2-yl claim 1 , pyrid-3-yl or pyrid-4-yl claim 1 , thiazolyl claim 1 , e.g. 1 claim 1 ,3-thiazolyl claim 1 , such as 1 claim 1 ,3-thiazol-2-yl or triazolyl claim 1 , e.g. 1 claim 1 ,2 claim 1 ,4-triazolyl such as 1 claim 1 ,2 claim 1 ,4-triazol-5-yl claim 1 , and particularly Y is phenyl.5. The compound of claim 1 , wherein Y is particularly unsubstituted or comprises at least one substituent which is selected from NH claim 1 , NHR claim 1 , N(R) claim 1 , OH and NO claim 1 , wherein Ris Calkyl or halo.7. The compound according to which comprises at least one detectable group.8. The compound according to claim 1 , which comprises at least one deuterium atom which is particularly a substituent of X or Y or a substituent of a group —NHor —NHR.9. The compound according to which comprises at least one F or F atom which is particularly a substituent selected from an F or F atom or a group comprising an F or F atom.10. The compound according to for use as an inhibitor of amyloid-β aggregate formation and/or as a modulator of amyloid surface properties claim 1 , and/or as an activator of degradation or reduction of amyloid-β aggregates.11. The compound for use according to any of claim 1 , wherein the disease is selected from Alzheimer's disease claim 1 , Parkinson's disease claim 1 , an amyloidosis such as αβ-amyloidosis claim 1 , primary systemic amyloidosis claim 1 , secondary systemic amyloidosis claim 1 , senile systemic amyloidosis claim 1 , familial amyloid polyneuropathy 1 claim 1 , ...

Подробнее
28-03-2013 дата публикации

HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR

Номер: US20130079306A1
Принадлежит: Individual

A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27 Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

Подробнее
28-03-2013 дата публикации

TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

Номер: US20130079374A1
Принадлежит: Takeda Pharmaceutical Company Limited

The present invention provides a compound represented by the formula 123-. (canceled)26. The compound of claim 24 , wherein Ris Calkyl optionally having substituent(s) claim 24 , Ccycloalkyl optionally having substituent(s) or Calkenyl optionally having substituent(s).27. The compound of claim 24 , wherein Ris a hydrogen atom or Calkyl optionally having substituent(s).28. The compound of claim 24 , wherein Ris a hydrogen atom or Calkyl optionally having substituent(s).29. The compound of claim 24 , wherein Ris a hydrogen atom claim 24 , a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s).30. The compound of claim 24 , wherein Ris a hydrogen atom claim 24 , Calkyl optionally having substituent(s) claim 24 , Calkenyl optionally having substituent(s) or amino optionally having substituent(s).31. The compound of claim 24 , wherein Rand Rare the same or different and each is a hydrogen atom claim 24 , a halogen atom claim 24 , hydroxy optionally having a substituent or Calkyl optionally having substituent(s).32. The compound of claim 24 , wherein Ris Calkyl optionally having substituent(s) claim 24 , Ccycloalkyl optionally having substituent(s) or Calkenyl optionally having substituent(s);{'sup': '2', 'Ris a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s);'}{'sup': '3', 'sub': 1-6', '2-6, 'Ris a hydrogen atom, Calkyl optionally having substituent(s), Calkenyl optionally having substituent(s) or amino optionally having substituent(s);'}{'sup': 4a', '4b, 'sub': '1-6', 'Rand Rare the same or different and each is a hydrogen atom, a halogen atom, hydroxy optionally having a substituent or Calkyl optionally having substituent(s);'}{'sup': '5', 'sub': '1-6', 'Ris a hydrogen atom or Calkyl optionally having substituent(s); and'}{'sup': '6', 'sub': '1-6', 'Ris a hydrogen atom or Calkyl optionally having substituent(s).'}33. The compound of claim ...

Подробнее
28-03-2013 дата публикации

Synthesis of Chirally Purified Substituted Benzothiazole Diamines

Номер: US20130079526A1
Принадлежит: Knopp Neurosciences Inc.

Methods for preparing chirally purified substituted 4,5,6,7-tetrahydro-benzothiazole diamines such as, for example, (6R)2-amino-4,5,6,7-tetrahydro--(propylamino)benzothiazole and purifying a dominant enantiomer of substituted 4,5,6,7-tetrahydro-benzothiazole diamines from entantiomerically enriched mixtures of substituted 4,5,6,7-tetrahydro-benzothiazole diamines are provided herein. 2. The process of claim 1 , wherein the alkyl sulfonate is a propyl sulfonate selected from n-propyl tosylate claim 1 , n-propyl methoxysulfonate and combinations thereof.3. The process of claim 1 , wherein the chirally purified substituted 4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydro-benzothiazole diamine is at least greater than about 97% chirally pure.4. The process of claim 1 , wherein the chirally purified substituted 4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydro-benzothiazole diamine is at least greater than about 99% chirally pure.5. The process of claim 1 , wherein the chirally purified substituted 4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydro-benzothiazole diamine is at least about 99.9% chirally pure.6. The process of claim 1 , wherein the chemical purity of the substituted 4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydro-benzothiazole diamine is greater than about 98%.7. The process of claim 1 , wherein the chemical purity of the substituted 4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydro-benzothiazole diamine is greater than about 99.9%.8. The process of claim 1 , wherein the chemical purity of the substituted 4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydro-benzothiazole diamine is greater than about 99.99%.9. The process of claim 1 , wherein the chemical purity of the substituted 4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydro-benzothiazole diamine is 100%.10. The process of claim 1 , wherein the substituted 4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydro-benzothiazole diamine is substantially free of achiral salts.11. The process of claim 1 , wherein the substituted 4 claim 1 ,5 ...

Подробнее
04-04-2013 дата публикации

Rubber Composition Comprising a Thiazole

Номер: US20130085223A1
Принадлежит:

A rubber composition for the manufacture of tires, based on one or more diene elastomers, on one or more reinforcing fillers and on a vulcanization system, the vulcanization system comprising one or more thiazole compounds of formula: 1. Rubber composition for the manufacture of tires , based on one or more diene elastomers , on one or more reinforcing fillers and on a vulcanization system , characterized in that the said vulcanization system comprises one or more thiazole compounds of formula:where{'sub': 1', '25, 'R1 and R2 independently represent H or a C-C-hydro-carbon group chosen from linear, branched or cyclic alkyl groups and aryl groups, optionally interrupted by one or more heteroatoms, it being possible for R1 and R2 to together form a non-aromatic ring,'} a linear or branched C1-C25 alkyl group which is optionally interrupted by one or more heteroatoms and which is optionally substituted by one or more cyclic C3-C10 alkyl or C6-C12 aryl groups, or', 'a cyclic C3-C10 alkyl group which is optionally interrupted by one or more heteroatoms and which is optionally substituted by one or more linear, branched or cyclic C1-C25 alkyl or C6-C12 aryl groups which are optionally interrupted by one or more heteroatoms., 'R3 represents2. The composition according to claim 1 , wherein R1 and R2 independently represent H or a methyl group.3. The composition according to claim 2 , wherein R1 and R2 each represent H.4. The composition according to claim 2 , wherein R1 and R2 each represent a methyl group.5. The composition according to claim 1 , wherein R3 represents a cyclohexyl group or a tert-butyl group.6. The composition according to claim 1 , wherein the thiazole compound or compounds are chosen from the compounds of formula (I) in which R3 represents a cyclohexyl and:R1 and R2 represent a methyl group, orR1 and R2 represent H, orR1 represents a methyl group and R2 represents H, orR1 represents H and R2 represents a methyl group.7. The composition according to claim ...

Подробнее
04-04-2013 дата публикации

CARBOXYLATION CATALYSTS

Номер: US20130085276A1
Принадлежит:

The use of a complex of the form Z—M—OR in the carboxylation of a substrate is described. The group Z is a two-electron donor ligand, M is a metal and OR is selected from the group consisting of OH, alkoxy and aryloxy. The substrate may be carboxylated at a C—H or N—H bond. The metal M may be copper, silver or gold. The two-electron donor ligand may be a phosphine, a carbene or a phosphite ligand. Also described are methods of manufacture of the complexes and methods for preparing isotopically labelled caboxylic acids and carboxylic acid derivatives. 134-. (canceled)25. A method of carboxylation of a substrate , the method comprising;{'sub': '2', 'contacting a complex of the form Z—M—OR ,wherein the group Z is a two-electron donor ligand, M is a metal, and OR is selected from the group consisting of OH, alkoxy and aryloxy; with a substrate and a source of CO.'}26. The method according to claim 25 , wherein the metal M is selected from the group consisting of copper claim 25 , silver and gold.27. The method according to claim 25 , wherein the carboxylation is carried out in the presence of a base.28. The method according to claim 27 , wherein the base is an alkali metal hydroxide or alkoxide.29. The method according to claim 25 , wherein the two-electron donor ligand Z is selected from the group consisting of phosphines claim 25 , carbenes claim 25 , or phosphites.30. The method according to claim 29 , wherein the two-electron donor ligand Z is a nitrogen containing heterocyclic carbene ligand.33. The method according to claim 26 , wherein the complex is selected from the group consisting of: [M(OH)(IMes)] claim 26 , [M(OH)(SIMes)] claim 26 , [M(OH)(IPr)] claim 26 , [M(OH)(ItBu)] claim 26 , and [M(OH)(SIPr)] claim 26 , where M is Au claim 26 , Ag or Cu.34. The method according to claim 25 , wherein the substrate is carboxylated at a C—H or N—H bond.35. The method according to claim 25 , wherein the substrate is a substituted or unsubstituted aromatic compound.36. The ...

Подробнее
11-04-2013 дата публикации

SOLID-PHASE FLUORINATION OF BENZOTHIAZOLES

Номер: US20130089501A1
Принадлежит:

The invention provides a process for the production of an F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I) 18-. (canceled)10. A radiopharmaceutical kit for the preparation of an F-labelled tracer for use in PET , which comprises:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, '(i) a vessel containing a compound of formula (I), (Ia), or (Ib) as defined in ; and'}{'sup': 18', '−, '(ii) means for eluting the vessel with a source of F;'}{'sup': 18', '−, '(iii) an ion-exchange cartridge for removal of excess F.'}11. A cartridge for a radiopharmaceutical kit for the preparation of an F-labelled tracer for use in PET which comprises:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, '(i) a vessel containing a compound of formula (I), (Ia), or (Ib) as defined in ; and'}{'sup': 18', '−, '(ii) means for eluting the vessel with a source of F.'}12. A radiopharmaceutical kit for the preparation of an F-labelled tracer for use in PET , which comprises:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, '(i) a vessel containing a compound of formula (III) as defined in ; and'}{'sup': 18', '−, '(ii) means for eluting the vessel with a source of F.'}13. A cartridge for a radiopharmaceutical kit for the preparation of an F-labelled tracer according to for use in PET which comprises:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, '(i) a vessel containing a compound of formula (III) as defined in ; and'}{'sup': '18', '(ii) means for eluting the vessel with a source of F.'}14. A method for obtaining a diagnostic PET image which comprises the step of using a radiopharmaceutical kit according to or a cartridge for a radiopharmaceutical kit according to . The present invention relates to novel solid-phase processes for the production of radiolabelled tracers, in particular for the production of F-labelled benzothiazole compounds which may be suitable for use as Positron Emission Tomography (PET) radiotracers. The invention also comprises ...

Подробнее
11-04-2013 дата публикации

Macrocyclic Inhibitors Of Hepatitis C Virus

Номер: US20130089520A1
Принадлежит: Medivir AB

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R 1 is —OR 7 , —NH—SO 2 R 8 ; R 2 is hydrogen, and where X is C or CH, R 2 may also be C 1-6 alkyl; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, C 3-7 cycloalkyl; R 4 is aryl or Het; n is 3, 4, 5, or 6; R 5 is halo, C 1-6 alkyl, hydroxy, C 1-6 alkoxy, phenyl, or Het; R 6 is C 1-6 alkoxy, or dimethylamino; R 7 is hydrogen; aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; R 8 is aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

Подробнее
11-04-2013 дата публикации

Pesticidal compositions

Номер: US20130089622A1
Принадлежит: DOW AGROSCIENCES LLC

This document discloses molecules having the following formula (“Formula I”):

Подробнее
11-04-2013 дата публикации

THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES

Номер: US20130090479A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and the compositions in the treatment of various disease, conditions, or disorders. The invention also relates to processes for preparing compounds of the inventions. 128-. (canceled) The present application is a continuation of U.S. patent application Ser. No. 12/538,396, filed Aug. 10, 2009, which is a divisional of U.S. patent application Ser. No. 11/786,464 filed Apr. 11, 2007,now U.S. Pat. No. 7,589,214, and which claims the benefit of U.S. Provisional Application No. 60,791.083, filed Apr. 11, 2006; each of which is incorporated by reference in its entirety.The present invention relates to compounds useful as inhibitors of protein kinases. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. The invention also relates to processes for preparing the compounds of the invention.The search for new therapeutic agents has been greatly aided in recent years by a better understanding of the structure of enzymes and other biomolecules associated with diseases. One important class of enzymes that has been the subject of extensive study is protein kinases.Protein kinases constitute a large family of structurally related enzymes that are responsible for the control of a variety of signal transduction processes within the cell. (See, Hardie, G. and Hanks, S. The Protein Kinase Facts Book, I and II, Academic Press, San Diego, Calif.: 1995). Protein kinases are thought to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The kinases may be categorized into families by the substrates they ...

Подробнее
18-04-2013 дата публикации

CYSTEINE DERIVATIVE

Номер: US20130095048A1
Принадлежит: AJINOMOTO CO., INC.

Cysteine compounds represented by the following formula 2. A cosmetic composition according to claim 1 , further comprising at least one ingredient selected from the group consisting of an oily component claim 1 , a surfactant claim 1 , an amino acid claim 1 , an amino acid derivative claim 1 , a lower alcohol claim 1 , a polyhydric alcohol claim 1 , a sugar alcohol claim 1 , an alkylene oxide adduct of a sugar alcohol claim 1 , a water-soluble polymer claim 1 , an antimicrobial agent claim 1 , a disinfectant claim 1 , an anti-inflammatory agent claim 1 , an analgesic claim 1 , an antifungal agent claim 1 , a stratum corneum peeling agent claim 1 , a skin colorant claim 1 , a hormone claim 1 , a UV absorber claim 1 , a hair-growth promoter claim 1 , a whitening agent claim 1 , an antiperspirant claim 1 , an astringent active ingredient claim 1 , a perspiration deodorant claim 1 , a vitamin claim 1 , a vasodilator claim 1 , a crude drug claim 1 , a pH adjuster claim 1 , a viscosity modifier claim 1 , a pearly pigment claim 1 , a natural perfume claim 1 , a synthetic perfume claim 1 , a dye claim 1 , an antioxidant claim 1 , a preservative claim 1 , am emulsifier claim 1 , a fat claim 1 , a wax claim 1 , a silicone compound claim 1 , a balm claim 1 , and a mixture thereof.3. A cosmetic composition according to claim 1 , wherein said at least one cysteine compound is one or more compounds selected from the group consisting of N-acetyl-2-methylthiazolidine-2 claim 1 ,4-dicarboxylic acid claim 1 , N-acetyl-2-methylthiazolidine-2 claim 1 ,4-dicarboxylic acid 2-ethyl ester claim 1 , and a salt thereof.4. A cosmetic composition according to claim 1 , wherein said at least one cysteine compound is one or more compounds selected from the group consisting of trans N-acetyl-2-methylthiazolidine-2 claim 1 ,4-dicarboxylic acid claim 1 , trans N-acetyl-2-methylthiazolidine-2 claim 1 ,4-dicarboxylic acid 2-ethyl ester claim 1 , and a salt thereof.6. A cosmetic composition according ...

Подробнее
18-04-2013 дата публикации

Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors

Номер: US20130096056A1
Принадлежит: Xenon Pharmaceuticals Inc

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where V, W, R 1 , R 2 , R 3 and R 4 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Подробнее
25-04-2013 дата публикации

METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE

Номер: US20130102617A1
Принадлежит: Astellas Pharma Inc.

Phenylacetamide compounds of the formula 1. (canceled)2. The method of claim 18 , wherein n is 0.3. The method of claim 2 , wherein Ris methyl claim 2 , trifluoromethyl claim 2 , or cyclopropyl.4. The method of claim 3 , wherein Ris cyclopropyl.6. The method of claim 5 , wherein Ring A is pyrazolyl claim 5 , thiazolyl claim 5 , thiadiazolyl claim 5 , pyridyl or pyrazinyl claim 5 , each of which may be substituted with up to five moieties independently selected from the group consisting of halogen claim 5 , cyano claim 5 , lower alkyl which may be substituted with —OR claim 5 , —OR claim 5 , —O-lower alkylene —OR claim 5 , and —C(O)R.7. The method of claim 6 , wherein [Chem. 21] is a single bond.8. The method of claim 6 , wherein [Chem. 22] is a double bond.9. The method of claim 18 , wherein the compound is selected from the group consisting of:(2E)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methylpyrazin-2-yl)-3-[(1S)-3-oxocyclopentyl]acrylamide,(2E)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(1-methyl-1H-pyrazol-3-yl)-3-[(1S)-3-oxocyclopentyl]acrylamide,(2E)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-fluoro-1,3-thiazol-2-yl)-3-[(1S)-3-oxocyclopentyl]acrylamide,(2R)—N-(4-acetyl-1,3-thiazol-2-yl)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methylpyridin-2-yl)-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methylpyrazin-2-yl)-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-[5-(hydroxymethyl)pyrazin-2-yl]-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)—N-(5-chloropyrazin-2-yl)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methoxypyrazin-2-yl)-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-3-[(1R)-3-hydroxycyclopentyl]-N-(5 ...

Подробнее
25-04-2013 дата публикации

Prophylactic or Ameliorating Agent for Genetic Diseases

Номер: US20130102644A1
Принадлежит: Masafumi Matsuo, Masatoshi Hagiwara

An object of the present invention is to provide a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation. The prophylactic or ameliorating agent used in the present invention is a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation, wherein the prophylactic or ameliorating agent contains a compound having a molecular weight of 1500 or lower.

Подробнее
02-05-2013 дата публикации

HAPTEN CONJUGATES FOR TARGET DETECTION

Номер: US20130109019A1
Принадлежит:

Embodiments of hapten conjugates including a hapten, an optional linker, and a peroxidase-activatable aryl moiety are disclosed. In some embodiments, the peroxidase-activatable aryl moiety is tyramine or a tyramine derivative. Embodiments of methods for making and using the hapten conjugates also are disclosed. In particular embodiments, the hapten conjugates are used in a signal amplification assay. In certain embodiments, the hapten is an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an azoaryl, a benzodiazepine, or 7-diethylamino-3-carboxycoumarin. The hapten is coupled to the peroxidase-activatable aryl moiety directly or indirectly via a linker. In certain embodiments, the hapten conjugates are used in multiplexed assays. 1. A hapten conjugate , comprising:a hapten selected from an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an azoaryl, a benzodiazepine, 2,3,6,7-tetrahydro-11-oxo-1H,5H,11H-[1]benzopyrano[6,7,8-ij]quinolizine-10-carboxylic acid, or 7-diethylamino-3-carboxycoumarin;a linker; anda tyramine or a tyramine derivative.2. (canceled)6. (canceled)811.-. (canceled)1332.-. (canceled)33. A method , comprising:(a) immobilizing a first peroxidase on a first target in a sample, wherein the first peroxidase is capable of reacting with a peroxidase-activatable aryl moiety;(b) contacting the sample with a solution comprising a first hapten conjugate, the first hapten conjugate comprising a first hapten selected from an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an ...

Подробнее
02-05-2013 дата публикации

C7-Fluoro Substituted Tetracycline Compounds

Номер: US20130109657A1
Принадлежит: Tetraphase Pharmaceuticals Inc

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

Подробнее
02-05-2013 дата публикации

SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF

Номер: US20130109710A1
Принадлежит: JAPAN TOBACCO INC.

The spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof 3. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed in claim 1 , wherein the number of the double bond in ring A of the spiro-ring AB is 0 or 1.4. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed in claim 1 , wherein the number of the double bond in ring B of the spiro-ring AB is 0 or 1.5. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed in claim 1 , wherein n3 is 1 or 2.6. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed claim 1 , wherein the spiro-ring AB may be substituted by 1 to 3 same or different substituent(s).7. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed in claim 1 ,{'sup': '1', 'wherein Ris'}(1) a hydrogen atom,{'sub': 1', '6, '(2) a C-Calkyl group,'}{'sub': 2', '6, '(3) a C-Calkenyl group,'}{'sub': 2', '6, '(4) a C-Calkynyl group,'}{'sub': 1', '6, '(5) a C-Calkoxy group,'}{'sub': 1', '6', '1', '6, '(6) a C-Calkoxy(C-C)alkyl group,'}{'sup': 11', '12', '11', '12, 'sub': 1', '6, '(7) —CONRRin which Rand Rare the same or different and each represents a hydrogen atom or a C-Calkyl group, or'}{'sub': 1', '6, '(8) a five-membered heteroaryl group which has at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, and which may be substituted by a C-Calkyl group.'}8. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed in claim 1 ,{'sup': '1', 'wherein Ris'}(1) a hydrogen atom,{'sub': 2', '6, '(2) a C-Calkenyl group,'}{'sub': 2', '6, '(3) a C-Calkynyl group,'}{'sub': 1', '6, '(4) a C-Calkoxy group or'}{'sub': 1', '6, '(5) a five- ...

Подробнее
16-05-2013 дата публикации

Compounds having trpv1 antagonistic activity and uses thereof

Номер: US20130123239A1
Автор: Noriyuki Kurose
Принадлежит: Shionogi and Co Ltd

The invention relates to compounds of Formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof.

Подробнее
16-05-2013 дата публикации

SUBSTITUTED ENAMINOCARBONYL COMPOUNDS

Номер: US20130123506A1
Принадлежит: Bayer CropScience AG

The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects. 1. A compound of formula (III){'br': None, 'sup': '1', 'sub': '2', 'HN(R)—CH-A\u2003\u2003(III)'}in whichA represents pyrid-3-yl that is optionally substituted in the 6-position by fluorine, chlorine, bromine or trifluoromethyl, or represents 1,3-thiazol-5-yl that is optionally substituted in the 2-position by chlorine; and{'sup': 1', '1, 'sub': 1', '3', '2', '3, 'Rhalo-C-C-alkyl or halo-C-C-alkenyl, with the proviso that Rmust be 2,2-difluoroethyl when A represents pyrid-3-yl that is substituted in the 6-position by chlorine.'}2. A compound of formula (III) according to claim 1 , in whichA represents 6-fluoropyrid-3-yl, 6-chloropyrid-3-yl, 6-bromopyrid-3-yl, 6-trifluoromethylpyrid-3-yl, 2-chloro-1,3-thiazol-5-yl; and{'sup': 1', '1, 'sub': 1', '3', '2', '3, 'Rrepresents fluorine-substituted C-C-alkyl or C-C-alkenyl, with the proviso that Rmust be 2,2-difluoroethyl when A represents 6-chloropyrid-3-yl.'}3. A compound which is N-[(6-chloropyridin-3-yl)methyl]-2 claim 1 ,2-difluoroethane-1-amine. This application is a continuation application of U.S. application Ser. No. 13/334,949, filed Dec. 22, 2011, which is a continuation application of U.S. application Ser. No. 12/295,355, filed Mar. 11, 2009, now U.S. Pat. No. 8,106,211, issued Jan. 31, 2012, which is a §371 National Stage Application of PCT/EP2007/002386 filed Mar. 19, 2007 which claims priority from German Application 10 2006 015 467.3 filed Mar. 31, 2006, the contents of each of these are hereby incorporated by reference in their entireties.1. Field of the InventionThe present application relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.2. Description of Related ...

Подробнее
23-05-2013 дата публикации

COMPOUNDS AND METHODS FOR ASSAYING REDOX STATE OF METABOLICALLY ACTIVE CELLS AND METHODS FOR MEASURING NAD(P)/NAD(P)H

Номер: US20130130289A1
Принадлежит: PROMEGA CORPORATION

The present invention provides compounds and methods for assaying redox state of metabolically active cells and methods for assaying enzyme activity and/or metabolite level by coupling to redox defining co-factor NAD(P)/NAD(P)H measurement. 146.-. (canceled)51. A method for analyzing the redox state of a metabolically active cellular sample:{'claim-ref': {'@idref': 'CLM-00047', 'claim 47'}, 'a. contacting the metabolically active cellular sample with a compound according to to form a first mixture;'}b. contacting the first mixture with a luciferase reaction mixture; andc. detecting bioluminescence.52. The method of claim 51 , wherein the metabolically active cellular sample comprises a cell claim 51 , a physiological fluid claim 51 , isolated organelles claim 51 , mitochondria or a mitochondrial complex or enzyme.53. The method of claim 51 , wherein the bioluminescence is indicative of cell viability.54. The method of claim 51 , wherein the metabolically active cellular sample is in an animal.55. A method for detecting cellular metabolites in a sample comprising claim 51 ,{'claim-ref': {'@idref': 'CLM-00047', 'claim 47'}, 'a. contacting the sample with a compound according to , an amplification enzyme system, NAD or NADP, diaphorase, and a luciferase reaction mixture; and'}b. detecting bioluminescence.56. The method of claim 55 , wherein the compound claim 55 , amplification enzyme claim 55 , diaphorase claim 55 , NAD or NADP and luciferase reaction mixture are in a single composition.57. A method of screening for a compound that affects cell toxicity claim 55 , cell viability or the redox state of a cell comprising:a. contacting a cell with a test compound to form a first mixture;{'claim-ref': {'@idref': 'CLM-00047', 'claim 47'}, 'b. contacting the first mixture a compound according to ;'}c. contacting the mixture of b) with a luciferase reaction mixture; andd. detecting a bioluminescent signal, wherein the signal is indicative of the test compound's effect on the ...

Подробнее
23-05-2013 дата публикации

SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF

Номер: US20130131044A1
Принадлежит:

The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. 2. The compound of wherein said non-interfering substituent is selected from one or more of the group consisting of alkyl claim 1 , cycloalkyl claim 1 , alkenyl claim 1 , cycloalkenyl claim 1 , alkynyl claim 1 , aryl claim 1 , heteroaryl claim 1 , arylalkyl claim 1 , heteroarylalkyl claim 1 , arylalkenyl claim 1 , heteroarylalkenyl claim 1 , arylalkynyl claim 1 , and heteroarylalkynyl claim 1 , each of which may be optionally substituted with one or more heteroatoms or additional non-interfering substituents.36-. (canceled)89-. (canceled)10. The compound of wherein the compound is selected from the following group:rac-(3aR,4R,5R,6R,7aS)-2-amino-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(ethylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-(propylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(butylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(allylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-((4-methoxybenzyl)amino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(dimethylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(ethyl(methyl)amino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;(3aR,4R,5R,6R,7aS)-2-amino-6-(hydroxymethyl)-3a,4,5,6,7 ...

Подробнее
23-05-2013 дата публикации

CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF

Номер: US20130131085A1
Принадлежит: ABBOTT LABORATORIES

The present invention features compounds of formula I 2. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate or prodrug thereof claim 1 , wherein said compound is selected from the group consisting of:tert-butyl(1S,3S,4S)-3-hydroxy-5-phenyl-1-(4-pyridin-2-ylbenzyl)-4-{[(1,3-thiazol-5-ylmethoxy) carbonyl]amino}pentylcarbamate;1,3-thiazol-5-ylmethyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-4-(acetylamino)-1-benzyl-2-hydroxy-5-phenylpentyl carbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-4-amino-1-benzyl-2-hydroxy-5-phenylpentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-2-hydroxy-4-[(methylsulfonyl)amino]-5-phenyl pentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-4-{[(dimethylamino)carbonyl]amino}-2-hydroxy-5-phenylpentylcarbamate;methyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-4-{[(dimethylamino)sulfonyl]amino}-2-hydroxy-5-phenylpentylcarbamate;tert-butyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;isobutyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;isopropyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;tert-butyl (1S,3R,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;1,3-thiazol-4-ylmethyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-4-ylmethoxy)carbonyl]amino}pentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-2-hydroxy-4-{[(2-isopropyl-1,3-thiazol-4-yl)acetyl]amino}-5-phenylpentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-4-{[(tert-butylamino)carbonyl]amino}-2-hydroxy-5-phenylpentylcarbamate;tert-butyl benzyl((2R,3S)-2-hydroxy-4-phenyl-3-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}butyl)carbamate;1,3- ...

Подробнее
23-05-2013 дата публикации

COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS

Номер: US20130131099A1
Принадлежит:

Nitrated and non-nitrated compounds capable of protecting brain tissue from injury and useful as therapeutic agents to treat neurodegenerative diseases and conditions are disclosed. Methods of using the compounds in therapeutic treatments, and methods of preparing the compounds, also are disclosed. 2. The compound of wherein Rand Rare taken together with the carbon to which they are attached to form a cyclopropyl ring.3. The compound of wherein Ris phenyl claim 1 , optionally substituted with one or more of halo claim 1 , benzyl claim 1 , N claim 1 , or triazolyl optionally substituted with pyridinyl.6. The compound of wherein Ris selected from the group consisting of F claim 5 , Cl claim 5 , Br claim 5 , Me claim 5 , OMe claim 5 , NO claim 5 , COEt claim 5 , COH claim 5 , COMe claim 5 , CONH claim 5 , CO(CH)NEt claim 5 , and H.7. The compound of selected from the group of compounds disclosed in paragraph [0176].17. A nitrated derivative of a compound of .18. The compound of selected form the group consisting of compounds disclosed in paragraph [0088].19. A method of treating a neurodegenerative or neurological disease or condition comprising administering a therapeutically affective amount of a compound of or to an individual in need thereof.20. A method of ameliorating symptoms and pathologies associated with brain injuries comprising administering a therapeutically affective amount of a compound of or to an individual in need thereof.21. A method of treating a disease or condition associated with cytokine therapy or cytokine overproduction comprising administering a therapeutically effective amount of a compound of or to an individual in need thereof.22. The method of wherein the compound of or is administered before claim 1 , during claim 1 , or after claim 1 , cytokine therapy.23. A method of enhancing cognition in an individual comprising administering a therapeutically affective amount of a compound of or to an individual in need thereof. This application ...

Подробнее
23-05-2013 дата публикации

O-CYCLOPROPYLCYCLOHEXYL-CARBOXANILIDES AND THEIR USE AS FUNGICIDES

Номер: US20130131124A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to O-CYCLOPROPYLCYCLOHEXYL-CARBOXANILIDES derivatives of formula (I); their process of preparation, their use as fungicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. 2. A compound of formula (I) as claimed in claim 1 , wherein{'sup': 1', '2, 'Rand Rare, independently, hydrogen or fluoro;'}{'sup': '3', 'sub': 2-6', '3-8, 'Ris Calkyl, optionally substituted Ccycloalkyl, phenyl, thienyl or furyl;'}A represents one of the radicals A1, A2, A3, A4, A5, A6, A9, A10, A11, A12 or A17;{'sup': '18', 'sub': 1', '2', '1', '2, 'Rrepresents hydrogen, cyano, fluorine, chlorine, bromine, iodine, methyl, ethyl, isopropyl, methoxy, ethoxy, methylthio, ethylthio, cyclopropyl, C-Chaloalkyl C-C-haloalkoxy having in each case 1 to 5 fluorine, chlorine and/or bromine atoms, trifluoromethylthio, difluoromethylthio, aminocarbonyl, aminocarbonylmethyl or aminocarbonylethyl;'}{'sup': '19', 'Rrepresents hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, methoxy, ethoxy, methylthio or ethylthio;'}{'sup': '20', 'sub': 1', '2, 'Rrepresents hydrogen, methyl, ethyl, n-propyl, isopropyl, C-C-haloalkyl having 1 to 5 fluorine, chlorine and/or bromine atoms, hydroxymethyl, hydroxyethyl, cyclopropyl, cyclopentyl, cyclohexyl or phenyl.'}{'sup': 21', '22, 'sub': 1', '2, 'Rand Rindependently of one another represent hydrogen, fluorine, chlorine, bromine, methyl, ethyl or C-C-haloalkyl having 1 to 5 fluorine, chlorine and/or bromine atoms;'}{'sup': '23', 'sub': 1', '2', '1', '2, 'Rrepresents fluorine, chlorine, bromine, cyano, methyl, ethyl, C-C-haloalkyl or C-C-haloalkoxy having in each case 1 to 5 fluorine, chlorine and/or bromine atoms;'}{'sup': 24', '25, 'sub': 1', '2, 'Rand Rindependently of one another represent hydrogen, fluorine, chlorine, bromine, methyl, ethyl or C-C-haloalkyl having 1 to 5 fluorine, chlorine and/or bromine atoms;'}{'sup ...

Подробнее
23-05-2013 дата публикации

LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY

Номер: US20130131321A1
Принадлежит: GRAFFINITY PHARMACEUTICALS GMBH

The present invention relates to the use for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) 2. The use of wherein Aris phenylene claim 1 , preferably methoxy-substituted phenylene.3. The use of wherein the C═O and the NH group are bonded to Arin meta position to each other.4. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris attached to the C═O group via a carbon ring atom which is adjacent to a ring heteroatom claim 1 , preferably a nitrogen or oxygen atom.5. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Arcontains two or more nitrogen atoms or one or more nitrogen atoms and an oxygen atom.6. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris N-methyl-substituted pyrazole claim 5 , pyridine claim 5 , isoxazole or oxadiazole.7. The use according to wherein the support material comprises a material selected from carbohydrates or crosslinked carbohydrates claim 1 , preferably agarose claim 1 , cellulose claim 1 , dextran claim 1 , starch claim 1 , alginate and carrageenan claim 1 , Sepharose claim 1 , Sephadex; synthetic polymers claim 1 , preferably polystyrene claim 1 , styrene-divinylbenzene copolymers claim 1 , polyacrylates claim 1 , PEG-Polycacrylate copolymers polymethacrylates claim 1 , polyvinyl alcohol claim 1 , polyamides and perfluorocarbons; inorganic materials claim 1 , preferably glass claim 1 , silica and metal oxides; and composite materials.8. The use according to wherein the protein is an antibody claim 1 , preferably an IgG type antibody claim 1 , or an Fc fusion protein.9. The use of wherein the purification is attained by binding of the ligand of the ligand-substituted matrix to an Fc fragment or domain of the antibody or the fusion protein.10. The use according to wherein the Fc ...

Подробнее
30-05-2013 дата публикации

HETEROARYL (ALKYL) DITHIOCARBAMATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Номер: US20130136794A1
Принадлежит: PEKING UNIVERSITY

Heteroaryl(alkyl)dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the description. The compounds are new tyrosine kinase inhibitors useful as an anti-tumor agents, preferably useful in the preparation of medicines for treating breast cancer, liver cancer, non-small cell lung cancer, gastric cancer, colon cancer, leukaemia or nasal cancer. 2. The compound according to claim 1 , wherein the group A is substituted or unsubstituted heterocyclic group claim 1 , is the heterocyclic group being selected from pyridyl claim 1 , pyrimidinyl claim 1 , pyrazinyl claim 1 , furyl claim 1 , oxazolyl claim 1 , pyrazolyl claim 1 , thiazolyl or oxadiazolyl; preferably the group A is substituted or unsubstituted pyridyl claim 1 , or pyridyl fused with benzene or morpholine ring claim 1 , the fused benzene or morpholine ring being unsubstituted or substituted with methyl.3. The compounds according to claim 2 , wherein the Calkyl is methyl claim 2 , the Calkoxy is methoxy claim 2 , the Calkoxycarbonyl is methoxycarbonyl claim 2 , and/or the Calkylamido is pentylamido .4. The compound according to claim 3 , wherein the Rgroup is cyano.5. The compound according to claim 1 , wherein the compound is:3-(furan-2-ylmethyl)-4-hydroxy-1,3-thiazinane-2-thione (compound 1);2-(methoxycarbonyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 2);2-cyanoethyl(furan-2-ylmethyl)dithiocarbamate (compound 3);3-(furan-2-ylmethyl)-4-hydroxy-4,5-dimethyl-3,4-dihydro-2H-1,3-thiazine-2-thione (compound 4);2-sulfamoylethyl(furan-2-ylmethyl)dithiocarbamate (compound 5);2-boronoethyl(furan-2-ylmethyl)dithiocarbamate (compound 6);2-(methylsulfinyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 7);2-(benzylsulfinyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 8);4-hydroxy-3-(pyridin-3-ylmethyl)-1,3-thiazinane-2-thione ( ...

Подробнее
30-05-2013 дата публикации

4-carboxybenzylamino derivatives as histone deacetylase inhibitors

Номер: US20130137690A1
Принадлежит: Individual

The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the 4-carboxybenzylamino derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the 4-carboxybenzylamino derivatives in vivo.

Подробнее
30-05-2013 дата публикации

Polymorphs of an Active Pharmaceutical Ingredient

Номер: US20130137734A1
Принадлежит: SANDOZ AG

The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions camprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat. 115-. (canceled)16. A crystalline form of Febuxostat having an X-ray powder diffraction pattern as measured using CuKα radiation comprising peaks at 2-theta angles of 6.6±0.2° , 12.8±0.2° , 24.5±0.2 , 25.8±0.2° , 26.6±0.2°.17. The crystalline form of Feboxostat according to characterized by an IR spectrum comprising absorption bands at wavenumbers of about 2960±2 cm claim 16 , 2874±2 cm claim 16 , 2535±2 cm claim 16 , 2229±2 cm claim 16 , 1673±2 cm claim 16 , 1605±2 cm claim 16 , 1509±2 cm claim 16 , 1422±2 cm claim 16 , 1368±2 cm claim 16 , 1323±2 cm claim 16 , 1274±2 cm claim 16 , 1166±2 cm claim 16 , 1116±2 cm claim 16 , 1045±2 cm claim 16 , 1013±2 cm claim 16 , 911±2 cm claim 16 , 820±2 cm claim 16 , 763±2 cmand 725±2 cm.18. The crystalline form of Febuxostat according to characterized by a moisture sorption/desorption curve as shown in .19. A pharmaceutical composition comprising a crystalline form of Febuxostat according to claim 16 , further comprising at least one pharmaceutically acceptable excipient.20. The pharmaceutical composition according to claim 19 , which is an oral dosage form preferably a capsule or a tablet.21. A process for the production of a pharmaceutical composition according to claim 19 , comprising the step of mixing a crystalline form of Febuxostat according to with a pharmaceutically acceptable excipient.22. A crystalline form of Febuxostat characterized by an X-ray powder diffraction pattern as measured using CuKα radiation comprising peaks at 2-theta angles of 2.9±0.2° claim 19 , 5.8±0.2° claim 19 ...

Подробнее
06-06-2013 дата публикации

Novel hydroxamates as therapeutic agents

Номер: US20130142758A1
Принадлежит: Pharmacyclics LLC

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

Подробнее
06-06-2013 дата публикации

INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS

Номер: US20130143765A1

Provided herein are methods for identifying compounds that are inhibitors of a calcium-activated chloride channel. Aminothiophene and aminothiazole compounds, and compositions comprising these compounds, described herein that inhibit efflux of chloride through a calcium-activated chloride channel are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased chloride and fluid secretion, for example, secretory diarrhea. 425-. (canceled)27. The composition of wherein at least one of Rand Ris not hydrogen.29112.-. (canceled)113. An isolated epithelial cell comprising (i) a calcium-activated chloride channel and (ii) a recombinant cytoplasmic indicator protein that binds halide.114. The epithelial cell of wherein the epithelial cell is an intestinal epithelial cell or a pulmonary epithelial cell.115. The epithelial cell of wherein the intestinal epithelial cell is an HT-29 cell.116. The epithelial cell of wherein the cytoplasmic indicator protein is a yellow fluorescent protein (YFP) mutant.117. The epithelial cell of claim 116 , wherein the YFP mutant is YFP-H148Q/I152L.118. The epithelial cell of wherein the calcium-activated chloride channel is TMEM16A.119. The epithelial cell of wherein TMEM16A is human TMEM16A.120. The epithelial cell of wherein the recombinant cytoplasmic indicator protein is introduced into the cell by a recombinant expression vector that is a viral vector.121. The method of wherein the viral vector is a retroviral vector.122. The method of wherein the retroviral vector is a lentiviral vector.123. A method of identifying an agent that is an inhibitor of a calcium-activated chloride channel comprising:{'claim-ref': {'@idref': 'CLM-00113', 'claim 113'}, '(a) contacting the isolated epithelial cell of and a candidate agent in a test sample to permit interaction between the candidate agent and the cell;'}{'sup': '2', '(b) adding to the test sample (i) at least one ...

Подробнее
06-06-2013 дата публикации

Guanidine compound

Номер: US20130143860A1
Принадлежит: Astellas Pharma Inc

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Подробнее
06-06-2013 дата публикации

COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM

Номер: US20130143927A1
Принадлежит: CalciMedica, Inc.

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. 4. The compound of wherein aryl is substituted with at least one Rselected from Cl claim 3 , Br claim 3 , F claim 3 , I claim 3 , CF claim 3 , C-Calkyl claim 3 , or OC-Calkyl.5. The compound of wherein aryl is substituted with at least one Rselected from Cl claim 3 , Br claim 3 , F claim 3 , and I.6. The compound of wherein Ris methyl.7. The compound of wherein Ris heteroaryl substituted with at least one R.8. The compound of wherein heteroaryl is selected from pyridyl claim 7 , pyrimidyl claim 7 , pyridazinyl claim 7 , pyrazinyl claim 7 , thienyl claim 7 , furyl claim 7 , pyranyl claim 7 , thiadiazolyl claim 7 , pyrazolyl claim 7 , imidazolyl claim 7 , thiazolyl claim 7 , isothiazolyl claim 7 , oxazolyl claim 7 , isoxazolyl claim 7 , indolyl claim 7 , indazolyl claim 7 , benzoxazolyl claim 7 , benzoisoxazolyl claim 7 , benzothiazolyl claim 7 , benzoisothiazolyl claim 7 , benzimidazolyl claim 7 , quinolyl claim 7 , pteridinyl claim 7 , pyrazolopyridinyl claim 7 , pyrazolopyrimidinyl claim 7 , imidazolothiazolyl claim 7 , quinoxazinyl claim 7 , and indolizinyl.9. The compound of wherein heteroaryl is pyridyl.10. The compound of wherein heteroaryl is substituted with at least one Rselected from Cl claim 8 , Br claim 8 , F claim 8 , and I.15. A pharmaceutical composition comprising a pharmaceutically acceptable diluent claim 1 , excipient claim 1 , or binder claim 1 , and a compound of or a pharmaceutically acceptable salt claim 1 , pharmaceutically acceptable prodrug claim 1 , or pharmaceutically acceptable solvate thereof.16. A method for treating a disease claim 1 , disorder or condition in a ...

Подробнее
13-06-2013 дата публикации

IMINOPROPENE COMPOUND AND USE THEREOF

Номер: US20130150392A1
Принадлежит: Sumitomo Chemical Company, Limited

The compound (I) or a salt thereof has an excellent controlling activity against pests. Then the compound (I) or a salt thereof is useful for an active ingredient of a pesticidal composition. 2. The compound according to claim 1 , wherein{'sup': 4', '5, 'sub': '2', 'X is SXor S(O)X'}{'sup': 4', '5', '21', 'A2', '21', 'A2, 'Xand Xare each independently a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower alkenyl group optionally substituted, a higher alkenyl group, a lower cycloalkenyl group optionally substituted, a lower alkynyl group optionally substituted, a higher alkynyl group, an aromatic hydrocarbon group optionally substituted, a heterocyclic group optionally substituted or C(=Q)X(wherein, Qis an oxygen atom, and Xis a lower alkyl group optionally substituted), group optionally substituted or a heterocyclic group optionally'}{'sup': 1', '1', 'I1, 'sub': '2', 'Y is OY(wherein, Yis a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower alkenyl group optionally substituted, a higher alkenyl group, a lower cycloalkenyl group optionally substituted, a lower alkynyl group optionally substituted, a higher alkynyl group, an aromatic hydrocarbon group optionally substituted, a heterocyclic group optionally substituted or N═C(Y),'}{'sup': B', 'B', 'F', 'F', 'G', 'H', 'G', 'H, 'sub': '2', 'Z is a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower alkenyl group optionally substituted, a higher alkenyl group, a lower cycloalkenyl group optionally substituted, a lower alkynyl group optionally substituted, a higher alkynyl group, an aromatic hydrocarbon group optionally substituted, a heterocyclic group optionally substituted, C(═O)OZ(wherein, Zis a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower ...

Подробнее
13-06-2013 дата публикации

Glutamate receptor modulators and therapeutic agents

Номер: US20130150416A1
Принадлежит:

The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds. 3. The method of wherein the disease or disorder is selected from the group consisting of cerebral deficits subsequent to cardiac bypass surgery and grafting claim 1 , cerebral ischemia claim 1 , stroke claim 1 , cardiac arrest claim 1 , spinal cord trauma claim 1 , head trauma claim 1 , perinatal hypoxia claim 1 , hypoglycemic neuronal damage claim 1 , AIDS-induced dementia claim 1 , ocular damage claim 1 , retinopathy claim 1 , muscular spasms claim 1 , convulsions claim 1 , migraine headaches claim 1 , urinary incontinence claim 1 , drug tolerance claim 1 , drug withdrawal claim 1 , drug cessation claim 1 , smoking cessation claim 1 , panic attack claim 1 , emesis claim 1 , brain edema claim 1 , neuropathic pain claim 1 , nociceptive pain claim 1 , Tourette's syndrome claim 1 , attention deficit disorder claim 1 , motor disorders claim 1 , tardive dyskinesia claim 1 , eating disorders claim 1 , sexual disorders claim 1 , obesity claim 1 , convulsive disorders claim 1 , circadian disorders claim 1 , neurodegenerative diseases claim 1 , amyelotrophic lateral sclerosis claim 1 , Parkinson's disease claim 1 , and multiple sclerosis claim 1 , ...

Подробнее
20-06-2013 дата публикации

HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS

Номер: US20130158075A1
Принадлежит: Piramal Enterprises Limited

The present invention relates to heterocyclic compounds of formula 1, in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, carboxylic acid isosteres and N-oxides. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof. 167-. (canceled)89. A compound according to claim 68 , wherein A is an aryl and said aryl is unsubstituted or substituted with one or more groups selected from halogen claim 68 , hydroxy claim 68 , (C-C)-alkoxy claim 68 , cyano claim 68 , (C-C)-alkyl claim 68 , OCF claim 68 , CF claim 68 , (C-C)-cycloalkyl claim 68 , aryl claim 68 , aryloxy claim 68 , heterocyclyl claim 68 , or O-heterocyclyl.90. A compound according to claim 68 , wherein A is an aryl group and said aryl group may be fused with an unsubstituted or substituted 5 or 6-membered cycloalkyl ring optionally containing one or more heteroatoms selected from O claim 68 , N or S.91. A compound according to claim 68 , wherein A is a heterocyclyl and said heterocyclyl is unsubstituted or substituted with one or more groups selected from halogen claim 68 , hydroxy claim 68 , (C-C)-alkoxy claim 68 , cyano claim 68 , (C-C)-alkyl claim 68 , (C-C)-cycloalkyl claim 68 , aryl claim 68 , aryloxy claim 68 , heterocyclyl or O-heterocyclyl.92. A compound according to claim 68 , wherein A is a (C-C)-cycloalkyl and said (C-C)-cycloalkyl is unsubstituted or substituted with one or more groups selected from halogen claim 68 , hydroxy ...

Подробнее
20-06-2013 дата публикации

METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO

Номер: US20130158082A1
Автор: Ye Keqiang
Принадлежит: EMORY UNIVERSITY

The disclosure relates to methods of managing blood sugar levels and compositions related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diabetes, insulin resistance, or hyperglycemia comprising administering to a subject diagnosed with, at risk of or exhibiting symptoms of diabetes, insulin resistance, or hyperglycemia a pharmaceutical composition comprising a compound comprising formula I. 2. The compound of claim 1 , wherein Rand Rare hydroxy substituted with formyl claim 1 , wherein formyl is substituted with R.3. The compound of claim 1 , wherein Ris a halogen.4. The compound of claim 1 , wherein Ris halogen.5. The compound of selected from:5,8-diacetyloxy-2,3-dichloro-1,4-naphthoquinone;5-acetyloxy-2,3-dichloro-1,4-naphthoquinone;2-((4-chlorophenyl)amino)naphtho[2,3-d]thiazole-4,9-dione, and2-((2,4-dichlorophenyl)amino)naphtho[2,3-d]thiazole-4,9-dione.6. A method of treating or preventing diabetes claim 1 , insulin resistance claim 1 , or hyperglycemia comprising administering to a subject diagnosed with claim 1 , at risk of claim 1 , or exhibiting symptoms of diabetes claim 1 , insulin resistance claim 1 , or hyperglycemia a pharmaceutical composition comprising a compound comprising formula I claim 1 , as provide in .7. The use of a compound as provided in in the production of a medicament for the treatment of diabetes claim 1 , insulin resistance claim 1 , or hyperglycemia.8. A pharmaceutical composition comprising a compound of formula I a provided in .10. The method of claim 9 , wherein X is NH.11. The method of claim 9 , wherein Ris carbocyclyl claim 9 , aryl claim 9 , or heterocyclyl optionally substituted R.12. The method of claim 9 , wherein Ris a halogen.13. The method of claim 9 , wherein Rand Rare not hydroxy or alkoxy.14. The method of claim 9 , wherein Rand Rare hydrogen.15. The method of claim 9 , wherein the subject is diagnosed with Type 1 or Type 2 diabetes. This application claims priority to U.S ...

Подробнее
20-06-2013 дата публикации

Aminodihydrothiazine derivatives

Номер: US20130158260A1
Принадлежит: Shionogi and Co Ltd

A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; E is lower alkylene; X is S, O, or NR′; R 1 is a hydrogen atom or lower alkyl; R 2a , R 2b , R 3a , R 3b , R 4a and R 4b is each independently a hydrogen atom, halogen, or hydroxy etc.; n and m are each independently an integer of 0 to 3; n+m is an integer of 0 to 3; R 5 is a hydrogen atom or substituted lower alkyl; its pharmaceutically acceptable salt, or a solvate thereof.

Подробнее
20-06-2013 дата публикации

METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND

Номер: US20130158272A1
Автор: Komiyama Masato
Принадлежит: TEIJIN PHARMA LIMITED

The present invention provides a method for producing a xanthine oxidase inhibitor, which is a therapeutic agent for hyperuricemia, or intermediates of the same, said method being efficient and using a short process. The present invention is a novel coupling method for obtaining a compound represented by formula (3) by bringing about a coupling reaction between a compound represented by formula (1) and a compound represented by formula (2), in the presence of a palladium compound, a ligand capable of coordinating to the palladium compound, a base, a C-Ccarboxylic acid, and at least one kind of additive. 2. The method of production according to claim 1 , wherein A is a Cto Calkyl group.3. The method of production according to claim 1 , wherein A is an isobutyl group.4. The method of production according to claim 1 , wherein X is an oxygen atom.5. The method of production according to claim 1 , wherein Ris a hydrogen atom.6. The method of production according to claim 1 , wherein Ris a cyano group.7. The method of production according to claim 1 , wherein Y represents a halogen atom claim 1 , —OCO—(Cto Calkyl group) claim 1 , —OCO— (phenyl group) claim 1 , —OSO—(Cto Calkyl group) claim 1 , —OSO-(phenyl group) claim 1 , or a diazonium group claim 1 , and claim 1 , in Y claim 1 , the Cto Calkyl group can be substituted with 1 to 3 halogen atoms claim 1 , and the phenyl group can be substituted with 1 to 5 optional substituents selected from halogen atoms and Cto Calkyl groups.9. The method of production according to claim 1 , wherein Ris COORand Ris a Cto Calkyl group.10. The method of production according to claim 1 , wherein Ris a methyl group.11. The method of production according to claim 1 , wherein the palladium compound is zerovalent palladium claim 1 , or a salt of monovalent or divalent palladium.12. The method of production according to claim 1 , wherein the palladium compound is palladium(II) acetate (Pd(OAc)) claim 1 , palladium(II) propionate (Pd(O(C═O)CHCH ...

Подробнее
27-06-2013 дата публикации

BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Номер: US20130165443A1
Принадлежит:

Compounds of the formula I: 2. The compound of claim 1 , wherein R claim 1 , Rand Rare hydrogen.3. The compound of claim 2 , wherein Ris phenyl substituted at the 4-position with methyl or halo and optionally substituted at the 2-position with halo.4. The compound of claim 2 , wherein Ris 4-methyl-phenyl.5. The compound of claim 2 , wherein Ris pyridin 2-yl substituted with methyl or halo at the 5-position.6. The compound of claim 2 , wherein Ris 5-methyl-pyridin-2-yl.8. The compound of claim 7 , wherein Ris hydrogen.9. The compound of claim 7 , wherein Ris methyl.10. The compound of claim 7 , wherein Ris: Calkyl; Calkyloxy-Calkyl; hydroxy-Calkyl; Calkylsulfanyl-Calkyl; Calkylsulfonyl-Calkyl; amino-Calkyl; N—Calkyl-amino-Calkyl; N claim 7 ,N-di-Calkyl-amino-Calkyl; Ccycloalkyl; optionally substituted phenyl; heteroaryl claim 7 , or heterocyclyl-Calkyl.11. The compound of claim 7 , wherein Ris: Calkyloxy-Calkyl; hydroxy-Calkyl; heteroaryl claim 7 , or heterocyclyl-Calkyl.12. The compound of claim 7 , wherein Ris methoxymethyl.13. The compound of claim 7 , wherein Ris hydroxymethyl.14. The compound of claim 7 , wherein Ris heteroaryl selected from pyridinyl claim 7 , pyrimidinyl claim 7 , or pyrazinyl claim 7 , each of which may be optionally substituted once or twice with methyl.15. The compound of claim 7 , wherein Ris hydroxymethyl claim 7 , methoxymethyl claim 7 , pyrazin-2-yl or 5-methyl-pyrazin-2-yl.16. The compound of claim 7 , wherein Ris Calkyl claim 7 , Ccycloalkyl or Ccycloalkyl-Calkyl.17. The compound of claim 7 , wherein Ris isopropyl claim 7 , isobutyl or tert butyl.18. The compound of claim 1 , wherein said compound is selected from:4-Methyl-thiophene-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;5-Methyl-thiophene-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;Furan-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;Thiophene-2- ...

Подробнее
27-06-2013 дата публикации

PREPARATION OF FEBUXOSTAT

Номер: US20130165662A1
Принадлежит:

Processes for preparing febuxostat. 2. The process of claim 1 , wherein a reaction medium comprises a Cto Clinear or branched chain alcohol.3. The process of claim 1 , wherein a reaction medium comprises isopropanol.4. The process of claim 1 , wherein a solid compound of Formula II is separated without cooling a reaction mass.5. The process of claim 1 , wherein a solid compound of Formula II is separated at about 30° C. to about 60° C.6. A process for purifying ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate by recrystallizing claim 1 , slurrying claim 1 , or both in a solvent comprising chloroacetyl chloride claim 1 , formic acid claim 1 , or ethyl 2-chloroacetoacetate.7. The process of claim 6 , wherein a solvent for purification comprises chloroacetyl chloride.8. Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate having a purity at least 99 percent by weight.10. A process for preparing febuxostat claim 6 , comprising hydrolyzing ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate in the presence of a ketone solvent.11. The process of claim 10 , wherein a ketone solvent comprises acetone claim 10 , ethyl methyl ketone claim 10 , or methyl isobutyl ketone.12. The process of claim 10 , wherein a ketone solvent is acetone.13. The process of claim 10 , wherein hydrolyzing comprises reacting with lithium hydroxide.14. The process of claim 13 , wherein lithium hydroxide is used in the form of an aqueous solution.15. A process for the preparation of crystalline Form III of febuxostat claim 13 , comprising recrystallizing febuxostat from a solution in a combination of an ester solvent and a hydrocarbon solvent.16. The process of claim 15 , wherein an ester solvent comprises ethyl acetate claim 15 , n-propyl acetate claim 15 , isopropyl acetate claim 15 , n-butyl acetate claim 15 , or tertiary-butyl acetate.17. The process of claim 15 , wherein a hydrocarbon solvent comprises toluene claim 15 , xylene claim 15 , n-hexane ...

Подробнее
04-07-2013 дата публикации

Cysteine protease inhibitors

Номер: US20130172232A1
Принадлежит: Medivir UK Ltd

Compounds of the formula I wherein R 2a and R 2b are independently H, halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl or C 1 -C 4 alkoxy, or R 2a and R 2b together with the carbon atom to which they are attached form a C 3 -C 6 cycloalkyl; R 3 is a C 5 -C 10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy; or R 3 is a C 2 -C 4 alkyl chain with at least 2 chloro or 3 fluoro substituents; or R 3 is C 3 -C 7 cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C 1 -C 4 alkyl, halo, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy; R 4 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino or; R 4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R 4 is Het, carbocyclyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy; n is 1, 2 or 3; for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Подробнее
04-07-2013 дата публикации

PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE

Номер: US20130172364A1
Принадлежит: TEVA PHARMACEUTICAL INDUSTRIES LTD.

Disclosed are novel derivatives of propargyl-trifluoromethoxy-amino-benzothiazole which are effective in treating neurologic disorders, including Parkinson's disease and multiple sclerosis. 2. The compound or a pharmaceutically acceptable salt of the compound according to claim 1 , wherein Ris N-containing heterocyclohexane.3. The compound or a pharmaceutically acceptable salt thereof according to claim 2 , wherein the N-containing heterocyclohexane is piperazine or piperidine.4. The compound or a pharmaceutically acceptable salt of the compound according to claim 3 , wherein Ris piperazine.6. The compound or a pharmaceutically acceptable salt of the compound according to claim 1 , wherein Ris —CHNR— claim 1 , and Ris selected from the group consisting of H and CH.9. The pharmaceutically acceptable salt of a compound according to which is a hydrochloride salt.10. The pharmaceutically acceptable salt of a compound according to which is a mesylate salt.11. A pharmaceutical composition comprising the compound of a pharmaceutically acceptable salt of and a pharmaceutically acceptable carrier.13. The process of claim 11 , wherein the first solvent is a mixture of toluene and acetic acid claim 11 , and the second solvent is toluene.15. The process of claim 13 , wherein the first solvent is THF claim 13 , the second solvent is ethanol claim 13 , the third solvent is CCl claim 13 , and the fourth solvent is acetonitrile.16. A method for treating a subject afflicted with an autoimmune disorder comprising administering to the subject a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof of so as to thereby treat the subject's autoimmune disorder.17. The method of claim 16 , wherein the autoimmune disorder is multiple sclerosis.18. The method of claim 16 , wherein the therapeutically effective amount is an amount from about 1 to about 1000 mg/day.19. The method of claim 16 , wherein the therapeutically effective amount is an amount from ...

Подробнее
04-07-2013 дата публикации

2-Alkyl-Cycloalk(en)yl-Carboxamides

Номер: US20130172367A1
Принадлежит: Bayer CropScience AG

Novel -alkylcycloalk(en)ylcarboxamides of the formula (I) 3. Composition for controlling unwanted microorganisms claim 1 , characterized in that it comprises at least one 2-alkylcycloalk(en)ylcarboxamide of the formula (I) according to claim 1 , in addition to extenders and/or surfactants.4. Use of 2-alkylcycloalk(en)ylcarboxamides of the formula (I) according to for controlling unwanted microorganisms.5. Method for controlling unwanted microorganisms claim 1 , characterized in that 2-alkyl-cycloalk(en)ylcarboxamides of the formula (I) according to are applied to the microorganisms and/or their habitat.6. Process for preparing compositions for controlling unwanted microorganisms claim 1 , characterized in that 2-alkylcycloalk(en)ylcarboxamides of the formula (I) according to are mixed with extenders and/or surfactants. The present invention relates to novel 2-alkylcycloalk(en)ylcarboxamides, to a plurality of processes for their preparation and to their use for controlling unwanted microorganisms.It is already known that numerous carboxamides have fungicidal properties (cf., for example, WO 98/03495, WO 98/03486 and EP-A 0 589 313). Thus, some 2-alkylcycloalkylcarboxamides are already known, such as, for example, N-(2-sec-butylcyclohexyl)-2-methyl-4,5-dihydrofuran-3-carboxamide from WO 98/03495, N-[2(2-ethylbutyl)cyclohexyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide from WO 98/03486 and N-2-sec-butylcyclohexyl)-2-methyl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide from EP-A 0 589 313. The activity of these compounds is good; however, in some cases, for example at low application rates, it is unsatisfactory.This invention now provides novel 2-alkylcycloalk(en)ylcarboxamides of the formula (I)in whichRrepresents hydrogen, halogen, hydroxyl, cyano, C-C-alkyl, C-C-haloalkyl, C-C-haloalkoxy or C-C-haloalkylthio having in each case 1 to 5 halogen atoms,Furthermore, it has been found that 2-alkylcycloalk(en)ylcarboxamides of the formula (I) are obtained whenR—X  ( ...

Подробнее
04-07-2013 дата публикации

PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE

Номер: US20130172571A1
Принадлежит: NATCO PHARMA LIMITED

Disclosed is a process for the preparation of Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate (I) the key intermediate for the preparation of [2-[3-cyano-4-(2-Methyl-propoxy)phenyl]-4-methyl-5-thiazole carboxylic acid (Febuxostat, I(A)) is approved under the trademark Uloric® by the US Food and Drug Administration for the treatment of hyperuricemia and gouty arthritis. 2. Process as claimed in wherein the step(a) comprises:i. Charging 98% formic acid and 3-bromo-4-hydroxy benzaldehyde and stirring for 15 minutesii. Charging hydroxylamine hydrochloride and sodium acetateiii. Heating reaction mass to 105° to 110° C. and maintaining for five hoursiv. Cooling reaction mass to room temperature and adding water and stirring for 2 hoursv. Filtering followed by drying and taking (XVII) to next stage3. Process as claimed in wherein the step(b) comprises:i. Charging Isopropyl alcoholic hydrogen chloride to the compound (XVII) and stirring for 15 minutesii. Charging thioacetamide and heating to 50-55° C.iii. Maintaining reaction mass at the same temperature for two hoursiv. Bringing reaction mass to room temperaturev. Charging water to the reaction mass and coolingvi. Filtering, washing with water and drying and taking compound (XVIII) to next stage4. Process as claimed in wherein the step(c) comprises:I. Charging Isopropyl alcohol to the compound of formula (XVIII) and stirring for 5 minutesII. Charging Ethyl-2-chloroacto acetate and heating to reflux temperatureIII. Maintaining five hours at reflux temperatureIV. Bringing reaction mass to room temperatureV. Filtering and drying to yield compound (XIX)5. Process as claimed in wherein the step(d) comprises:I. Charging compound (XIX) and DMFII. Charging potassium carbonate and Isobutyl bromideIII. Heating reaction mass to 80-85° C. and maintaining for six hoursIV. Bringing reaction mass to room temperature and quenching into waterV. Filtering and washing with waterVI. Suspending wet salt in a ...

Подробнее
11-07-2013 дата публикации

Crystalline forms of febuxostat

Номер: US20130178504A1
Принадлежит: Teva Pharmaceutical Industries LTD

New forms of Febuxostat have been prepared and characterized. These forms are useful, for example, in the chronic management of hyperuricemia in patients with gout.

Подробнее
11-07-2013 дата публикации

Compounds for the Inhibition of Cellular Proliferation

Номер: US20130178505A1

Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein. 4. (canceled)9. (canceled)10. (canceled)13. (canceled)14. (canceled)1719.-. (canceled)28. A method of treating a cellular proliferative disorder in a human or non-human mammal in need thereof claim 23 , the method comprising administering to the human or non-human mammal a compound of .29. The method of wherein the compound is administered by inhalation claim 28 , transdermally claim 28 , orally claim 28 , rectally claim 28 , transmucosally claim 28 , intestinally claim 28 , parenterally claim 28 , intramuscularly claim 28 , subcutaneously or intravenously.30. The method of claim 28 , wherein said cellular proliferative disorder is cancer.31. (canceled)32. A method of inhibiting translation in a human or non-human mammal comprising administering to the human or non-human mammal a compound of .33. A method of inhibiting proliferation of cells comprising contacting the cells with a compound of .34. The method of wherein the cells are cancer cells. This application claims priority to U.S. Provisional Patent Application No. 61/359,227, filed on Jun. 28, 2010 and is hereby incorporated herein by reference in its entirety for all purposes.This invention was made with Government support under Grant Number R01 CA121357 awarded by the National Institutes of Health. The Government has certain rights in the invention.The present invention relates to novel compounds which inhibit translation initiation, pharmaceutical compositions of the novel compounds, and methods of treating medical disorders.The regulation of protein synthesis at the level of ...

Подробнее
18-07-2013 дата публикации

METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS

Номер: US20130183753A1
Принадлежит: KYOTO UNIVERSITY

The present invention relates to a composition for promoting differentiation of pluripotent stem cells into cardiac muscle cells, and a method for inducing differentiation of pluripotent stem cells into cardiac muscle cells and a method for preparing cardiac muscle cells. 2. The method according to claim 1 , wherein{'sub': 6', '9', '12', '11', '12', '13', '6', '9', '2', '2', '2, 'Rto Rare each independently a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; a linear or branched alkyl group having 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom; or a group —NRR, wherein Rand Rare each independently a hydrogen atom, an oxygen atom, or a linear or branched alkyl group having 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom; wherein two adjacent groups among Rto Rmay join together to form —O—CH—O— or —O—(CH)—O—.'}3. The method according to claim 2 , wherein{'sub': 1', '5', '1', '5', '2', '2', '2, 'Rto Rare each independently a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or a linear or branched alkyl group having 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom; wherein two adjacent groups among Rto Rmay join together to form —O—CH—O— or —O—(CH)—O—, and'}{'sub': 15', '15, 'X is an oxygen atom; a sulfur atom; or a group —NR, wherein Ris a hydrogen atom, a linear or branched alkyl group having 1 to 5 carbon atoms, or a linear or branched acyl group having 1 to 5 carbon atoms.'}4. The method according to claim 3 , wherein{'sub': 2', '3', '2', '3', '2', '2', '2, 'Rand Rare a linear or branched alkoxy group having 1 to 5 carbon atoms, or Rand Rjoin together to form —O—CH—O— or —O—(CH)—O—,'}{'sub': 6', '9, 'Rand Rare each independently, a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or a linear or ...

Подробнее
18-07-2013 дата публикации

COMPOUND HAVING DETRUSOR MUSCLE-CONTRACTING ACTIVITY AND URETHRAL SPHINCTER MUSCLE-RELAXING ACTIVITY

Номер: US20130184236A1
Принадлежит: ONO PHARMACEUTICAL CO., LTD.

Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder. 2. The compound of claim 1 , wherein the compound is(1) 2-[(2-{(1R,5R)-2-oxo-5-[(1E)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid,(2) 2-[(2-{(1R,5R)-2-oxo-5-[(1E,4S)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid, or(3) 2-[(2-{(1R,5R)-2-oxo-5-[(1E,4R)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid.3. The mixture in an arbitrary ratio of claim 1 , wherein the compound is 2-[(2-{(1R claim 1 ,5R)-2-oxo-5-[(1E claim 1 ,4S)-7 claim 1 ,8 claim 1 ,8-trifluoro-4-hydroxy-4-methyl-1 claim 1 ,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1 claim 1 ,3-thiazole-4-carboxylic acid and the diastereomer is 2-[(2-{(1S claim 1 ,5R)-2-oxo-5-[(1E claim 1 ,4S)-7 claim 1 ,8 claim 1 ,8-trifluoro-4-hydroxy-4-methyl-1 claim 1 ,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1 claim 1 ,3-thiazole-4-carboxylic acid.5. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is an agent for contracting the bladder detrusor and ...

Подробнее
18-07-2013 дата публикации

Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels

Номер: US20130184258A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. 275-. (canceled)76. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable adjuvant or carrier.77116-. (canceled) The present application claims the benefit under 35 U.S.C. §119 of U.S. Provisional patent application No. 60/493,659, filed Aug. 8, 2003, and U.S. Provisional patent application No. 60/584,717, filed Jul. 1, 2004, the entire contents of both applications being incorporated herein by reference.The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Na channels are central to the generation of action potentials in all excitable cells such as neurons and myocytes. They play key roles in excitable tissue including brain, smooth muscles of the gastrointestinal tract, skeletal muscle, the peripheral nervous system, spinal cord and airway. As such they play key roles in a variety of disease states such as epilepsy (See, Moulard, B. and D. Bertrand (2002) “Epilepsy and sodium channel blockers” 12(1): 85-91)), pain (See, Waxman, S. G., S. Dib-Hajj, et al. (1999) “Sodium channels and pain” 96(14): 7635-9 and Waxman, S. G., T. R. Cummins, et al. (2000) “Voltage-gated sodium channels and the molecular pathogenesis of pain: a review” 37(5): 517-28), myotonia (See, Meola, G. and V. Sansone (2000) “Therapy in myotonic disorders and in muscle channelopathies” 21(5): S953-61 and Mankodi, A. and C. A. Thornton (2002) “Myotonic syndromes” 15(5): 545-52), ataxia (See, Meisler, M. H., J. A. ...

Подробнее
18-07-2013 дата публикации

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Номер: US20130184278A1
Принадлежит: ABBOTT LABORATORIES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. 5. The compound of claim 1 , or therapeutically acceptable salt thereof claim 1 , wherein the compound is selected from the group consisting of:4-[4-(cyclohexylmethyl)-4-methoxypiperidin-1-yl]-N-{[5-({(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl}amino)-4-nitrothien-2-yl]sulfonyl}benzamide;N-{[5-({(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl}amino)-4-nitrothien-2-yl]sulfonyl}-4-[4-methoxy-4-(3-methylbenzyl)piperidin-1-yl]benzamide;N-{[5-({(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl}amino)-4-nitrothien-2-yl]sulfonyl}-4-[4-(3,3-diphenylprop-2-enyl)piperazin-1-yl]benzamide;4-{4-[(4′-chloro-1,1′-biphenyl-2-yl)methyl]piperazin-1-yl}-N-[(4-{[2-(phenylthio)ethyl]amino}piperidin-1-yl)sulfonyl]benzamide;N-[(4-{acetyl[2-(phenylthio)ethyl]amino}piperidin-1-yl)sulfonyl]-4-{4-[(4′-chloro-1,1′-biphenyl-2-yl)methyl]piperazin-1-yl}benzamide;4-{4-[(4′-chloro-1,1′-biphenyl-2-yl)methyl]piperazin-1-yl}-N-[(4-{methyl[2-(phenylthio)ethyl]amino}piperidin-1-yl)sulfonyl]benzamide;4-{4-[(4′-chloro-1,1′-biphenyl-2-yl)methyl]piperazin-1-yl}-N-{[5-({(1R)-3-[isopropyl(methyl)amino]-1-[(phenylthio)methyl]propyl}amino)-4-nitrothien-2-yl]sulfonyl}benzamide;4-(4-{[2-(4-chlorophenyl)cyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-{[5-({(1R)-3-[isopropyl(methyl)amino]-1-[(phenylthio)methyl]propyl}amino)-4-nitrothien-2-yl]sulfonyl}benzamide;4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-{[5-({(1R)-3-[isopropyl(methyl)amino]-1-[(phenylthio)methyl]propyl}amino)-4-nitrothien-2-yl]sulfonyl}benzamide;N-{[(5Z)-5-(acetylimino)-4-methyl-4,5-dihydro-1,3,4-thiadiazol-2-yl]sulfonyl}-4-{4-[(4′-chloro-1,1′-biphenyl-2-yl)methyl]piperazin-1-yl}benzamide;N-({5-[(benzoylamino)methyl]thien-2-yl}sulfonyl)-4-{4-[(4′-chloro-1,1′-biphenyl-2-yl)methyl]piperazin-1-yl ...

Подробнее
18-07-2013 дата публикации

Sulfonyl compounds which modulate the cb2 receptor

Номер: US20130184315A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of formula (I) and formula (II) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Подробнее
18-07-2013 дата публикации

PROCESS FOR PREPARING THE CRYSTALLINE FORM II OF FEBUXOSTAT

Номер: US20130184466A1
Принадлежит: INTERQUIM, S.A.

The present invention relates to a novel process for preparing the crystalline form II of febuxostat by crystallization of a solvent selected from ethyl acetate, methyl acetate or ethyl formiate. 1. A process for preparing the crystalline form II of febuxostat , comprising the following steps:a) Dissolving febuxostat in a solvent selected from the group consisting of ethyl acetate, methyl acetate and ethyl formiate in a proportion from 10 to 60 ml of solvent per gram of solute, at a temperature between 50° C. and boiling temperature of the solution;b) Forming the crystals by cooling the solution from step a) at a temperature between 20° C. and 45° C., optionally over a period of 0.5-2 hours under stirring;c) Cooling the suspension from step b) at a temperature between 0° C. and 30° C. over a period of 0.5-3 hours; andd) Isolating the crystalline form II of febuxostat by filtration and drying.2. The process according to claim 1 , step a) claim 1 , wherein the proportion of solvent per gram of solute is from 15 to 50 ml.3. The process according to claim 1 , step b) claim 1 , wherein the temperature ranges from 33° C. to 37° C.4. The process according to claim 1 , step b) claim 1 , wherein the period is 1 hour.5. The process according to claim 1 , which comprises -between step b) and step c)-increasing yield of step b) by eliminating 40-80% of the solvent by distillation under reduced pressure at a temperature between 30° and 40° C.6. The process according to claim 5 , wherein the temperature ranges from 33° C. to 37° C. The present invention relates to a process for preparing the crystalline form II of febuxostat (2-[3-cyano-4-(2-i-butoxy)phenyl]-4-methyl-5-thiazole-carboxylic acid). Febuxostat is an inhibitor of xanthine oxidase that is indicated in the treatment of hyperuricemia. Its structural formula is as follows:CN101139325A relates to two crystalline forms of febuxostat by using ethanol, ethyl acetate or acetone. Among them form II is described, but operational ...

Подробнее
25-07-2013 дата публикации

TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES

Номер: US20130189246A1
Автор: Petrukhin Konstantin

Provided are compositions and methods for treatment of ophthalmic conditions, such as retinal detachment and age-related macular degeneration. Various fluorenone derivatives described herein can stimulate fluid removal from the subretinal space and down-regulate reactive gliosis. Administration of compounds described herein can provide an alternative or an adjunct to an invasive procedure to reattach the retina. 2. The method according to claim 1 , wherein X is selected from the group consisting of propyl claim 1 , hydroxyethyl claim 1 , haloethyl claim 1 , and cycloalkyl having less than 6 carbons.32. The method according to any one of - wherein R is a heterocyclic-alkyl group.43. The method according to any one of - wherein R is an oxazinyl-alkyl group.5. The method according to wherein the compound is selected from the group consisting of:2-{[(5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1H-fluoren-7-yl)oxy]methyl}-tetrahydro-1,3-oxazine;2-{[(5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1H-fluoren-7-yl)oxy]methyl}oxazoline;2-{[(5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1H-fluoren-7-yl)oxy]methyl}thiazoline;enantiomers thereof; andpharmaceutically acceptable salts thereof.63. The method according to any one of - wherein R is a pyridyl-alkyl group.7. The method according to wherein the compound is selected from the group consisting of:5,6-dichloro-9a-propyl-7-(2-pyridylmethoxy)-2,3,9,9a-tetrahydro-1H-fluoren-3-one;5,6-dichloro-9a-propyl-7-(3-pyridylmethoxy)-2,3,9,9a-tetrahydro-1H-fluoren-3-one;5,6-dichloro-9a-propyl-7-(4-pyridylmethoxy)-2,3,9,9a-tetrahydro-1H-fluoren-3-one;enantiomers thereof; andpharmaceutically acceptable salts thereof.82. The method according to any one of - wherein R is a heterocyclicaralkyl group.9. The method according to wherein the compound is selected from the group consisting of:5,6-dichloro-2,3,9,9a-tetrahydro-7-[4-(2-oxazolinyl)-phenylmethoxy]-9a-propyl-1H-fluoren-3-one;5,6-dichloro-2,3,9,9a-tetrahydro-7-[3-(2-oxazolinyl ...

Подробнее
25-07-2013 дата публикации

ENZYMATIC CONJUGATION OF POLYPEPTIDES

Номер: US20130189287A1
Принадлежит:

The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions 1. An antibody or antibody fragment comprising a functionalized acceptor glutamine residue , the functionalized acceptor glutamine residue having Formula IVa ,{'br': None, 'sub': n', 'z', 'q', 'q', 'r, '(Q)-NH—(C)—X-L-(V—(Y—(Z))))\u2003\u2003Formula IVa'}or a pharmaceutically acceptable salt or solvate thereof,wherein:Q is glutamine residue present in an antibody or antibody fragment;{'sub': 'n', '(C)is a substituted or unsubstituted alkyl or heteroalkyl chain, optionally wherein any carbon of the chain is substituted with an alkoxy, hydroxyl, alkylcarbonyloxy, alkyl-S—, thiol, alkyl-C(O)S—, amine, alkylamine, amide, or alkylamide;'}n is an integer selected from among the range of 2 to 20;X is NH, O, S, absent, or a bond;L is independently absent, a bond or a continuation of a bond, or a carbon comprising framework of 5 to 200 atoms substituted at one or more atoms;r is an integer selected from among 1, 2, 3 or 4;q is an integer selected from among 1, 2, 3 or 4;z is an integer selected from among 1, 2, 3 or 4; andV is independently absent, a bond or a continuation of a bond, a non-cleavable moiety or a conditionally-cleavable moiety;Y is independently absent, a bond or a continuation of a bond, or a spacer system which is comprised of 1 or more spacers; andZ is a moiety that improves pharmacokinetic properties, a therapeutic moiety or a diagnostic moiety, wherein Z is an organic compound that is electrically negatively charged, hydrophobic and/or that has a molecular weight of at least 400 g/mol.2. The antibody of claim 1 , wherein n is an integer selected from among the range of 10 to 20.3. The antibody of claim 1 , wherein (C)is a heteroalkyl chain that comprises a (CH—CH—O—)group claim 1 , wherein x is ...

Подробнее
25-07-2013 дата публикации

SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF

Номер: US20130190366A1
Принадлежит: CADILA HEALTHCARE LIMITED

Substantially pure salts of febuxostat of Formula (IA): wherein Y is Na, K, Li, Mg, Ca, Zn, Ba, Sr, choline, epolamine and N(R)and processes for preparation thereof are disclosed. 3. Febuxostat sodium having purity greater than 99.5% by area percentage of HPLC.5. Febuxostat potassium having purity greater than 99.5% by area percentage of HPLC.7. The process as claimed in claim 6 , wherein the base comprises one or more of sodium hydroxide claim 6 , potassium hydroxide claim 6 , lithium hydroxide claim 6 , calcium hydroxide claim 6 , barium hydroxide claim 6 , strontium hydroxide claim 6 , zinc hydroxide claim 6 , choline hydroxide claim 6 , epolamine hydroxide claim 6 , sodium carbonate claim 6 , potassium carbonate claim 6 , lithium carbonate claim 6 , magnesium carbonate claim 6 , calcium carbonate claim 6 , sodium bicarbonate claim 6 , potassium bicarbonate claim 6 , lithium bicarbonate claim 6 , sodium methoxide claim 6 , potassium t-butoxide claim 6 , magnesium methoxide claim 6 , and the like.8. The process as claimed in claim 6 , wherein the organic solvent comprises one or more of aliphatic alcohols claim 6 , aliphatic ketones claim 6 , polar aprotic solvents claim 6 , or mixtures thereof.9. The process as claimed in claim 8 , wherein the alcohol comprises one or more of methanol claim 8 , ethanol claim 8 , n-propanol claim 8 , isopropanol claim 8 , n-butanol claim 8 , and tert-amyl alcohol.10. The process as claimed in claim 8 , wherein the aliphatic ketones comprises one or more of acetone claim 8 , methylethylketone claim 8 , and methylisobutyl ketone.11. The process as claimed in claim 8 , wherein the polar aprotic solvent comprises one or more of dimethylformamide claim 8 , dimethylacetamide claim 8 , dimethylsulfoxide claim 8 , and N-methylpyrrolidone.12. The process as claimed in claim 6 , wherein the isolation comprises one or more of filtration claim 6 , filtration under vacuum claim 6 , evaporation claim 6 , decantation claim 6 , centrifugation ...

Подробнее
25-07-2013 дата публикации

FLUORINATED THIAZOLES FOR USE IN TREATING CANCER

Номер: US20130190367A1
Принадлежит:

Compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, where: Ris selected from the group consisting of: phenyl, and phenyl mono-, di-, or tri-substituted by a radical independently selected from the group consisting of F, Cl, Br, I, (C-C)-alkyl, COO-(C-C)-alkyl, and (C-C)-alkoxy; and Ris a radical selected from the same group as R, further including a phenyl substituted in 4-position by a radical independently selected from the group consisting of —O(CH)CONH(CH)CHand OCHCOOC(CH), a biphenyl-4-yl, thiazol-2-yl, and a thiazol-2-yl mono- or di-substituted by a radical selected from F and phenyl; inhibit cell proliferation of tumor cells independently of p53 protein and may also induce apoptosis in several tumor cells independently of p53 protein, being useful for the treatment of several types of cancer. 2. The compound of formula (I) as defined in claim 1 , wherein: Ris a radical selected from the same group as R claim 1 , further including a biphenyl-4-yl claim 1 , a thiazol-2-yl claim 1 , and a thiazol-2-yl mono- or di-substituted claim 1 , in 4 or 5 positions claim 1 , by a radical selected from the group consisting of F and phenyl.3. The compound according to claim 2 , wherein Ris selected from the group consisting of: phenyl claim 2 , and phenyl mono-substituted by a radical independently selected from the group consisting of Cl claim 2 , (C-C)-alkyl claim 2 , and —COO-(C-C)-alkyl.4. The compound according to claim 3 , wherein Ris selected from the group consisting of: phenyl claim 3 , 4-ethylphenyl claim 3 , 4-chlorophenyl claim 3 , 2-methylphenyl claim 3 , 4-methylphenyl claim 3 , 2-ethoxyphenylcarbonyl claim 3 , and 4-ethoxyphenylcarbonyl.5. The compound according to claim 2 , wherein Ris a radical selected from the group consisting of: phenyl claim 2 , and phenyl mono-substituted by a radical independently selected from the group consisting of Cl claim 2 , (C-C)-alkyl claim 2 , and COO-(C-C)- ...

Подробнее
25-07-2013 дата публикации

NOVEL POLYMORPHS OF FEBUXOSTAT

Номер: US20130190368A1
Принадлежит: HETERO RESEARCH FOUNDATION

The present invention provides a novel 1,4-dioxane solvate form of febuxostat and process for its preparation. The present invention also provides novel crystalline forms of febuxostat, processes for their preparation and pharmaceutical compositions comprising them. 1. A febuxostat 1 ,4-dioxane solvate form , characterized by peaks in the powder x-ray diffraction spectrum having 2θ angle positions at about 4.8 , 6.7 , 11.5 , 15.8 and 25.9±0.2 degrees.2. A febuxostat 1 ,4-dioxane solvate form , characterized by an x-ray powder diffractogram as shown in .3. A process for the preparation of febuxostat 1 claim 1 ,4-dioxane solvate form as claimed in claim 1 , which comprises crystallizing febuxostat from 1 claim 1 ,4-dioxane solvent and isolating febuxostat 1 claim 1 ,4-dioxane solvate form.4. A febuxostat crystalline form H1 claim 1 , characterized by peaks in the powder x-ray diffraction spectrum having 2θ angle positions at about 5 claim 1 ,7 claim 1 , 7.9 claim 1 , 11 claim 1 ,4 claim 1 , 12.6 claim 1 , 17.7 claim 1 , 20.4 claim 1 , 24.6 and 25.7±0.2 degrees.5. A febuxostat crystalline form H1 claim 1 , characterized by an x-ray powder diffractogram as shown in .6. A process for the preparation of febuxostat crystalline form H1 as claimed in claim 4 , which comprises:a. providing a solution of febuxostat in an ester solvent;b. heating the solution obtained in step (a) at reflux;c. cooling the reaction mass obtained in step (b) at below 20° C.; andd. isolating febuxostat crystalline form H1.7. The process as claimed in claim 6 , wherein the ester solvent used in step (a) is a solvent or mixture of solvents selected from ethyl acetate claim 6 , methyl acetate claim 6 , isopropyl acetate claim 6 , tert-butyl methyl acetate and ethyl formate.8. The process as claimed in claim 7 , wherein the ester solvent is ethyl acetate.9. The process as claimed in claim 6 , wherein the step (c) is carried out at about 0 to 10° C.10. The process as claimed in claim 9 , wherein the ...

Подробнее
25-07-2013 дата публикации

APOPTOSIS PROMOTERS

Номер: US20130190488A1
Принадлежит: ABBOTT LABORATORIES

Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member. 19-. (canceled)10. A compound , or a therapeutically acceptable salt thereof , wherein the compound is selected from the group consisting of:N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(5,6-dihydro-1(4H)-pyrimidin-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(2,4-dimenthyl-4,5-dihydro-1H-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-methyl-4,5-dihydro-1H-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(4,4-dimethyl-4,5-dihydro-1H-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-1-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)oxy)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((2-(4-chlorophenyl)cyclohept-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;4-(((1R)-3-(bis(2-methoxyethyl)amino)-1 ...

Подробнее
01-08-2013 дата публикации

CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS

Номер: US20130197013A1
Принадлежит:

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection. 4. The compound of wherein (G) is a heterocyclyl.5. (canceled)6. The compound of wherein (G) is phenyl.78-. (canceled)9. The compound of wherein E is —X═X— claim 1 , and X claim 1 , X claim 1 , Xand Xare independently C(R2) or N.10. The compound of wherein E is —X═X— claim 1 , and X claim 1 , X claim 1 , Xand Xare independently C(R2).1112-. (canceled)13. The compound of wherein E is —S— claim 1 , and Xand Xare independently C(R2) or N.1420-. (canceled)21. The compound of wherein each (R1) is independently chosen from alkyl claim 1 , aryl claim 1 , amino claim 1 , amido claim 1 , nitro claim 1 , halo claim 1 , haloalkyl claim 1 , haloalkoxy claim 1 , cyano claim 1 , heterocycle claim 1 , sulfonyl claim 1 , sulfonamide claim 1 , hydroxyl claim 1 , or alkoxy.22. The compound of wherein each (R1) is independently chosen from —CF claim 1 , —F claim 1 , —Cl claim 1 , —CN claim 1 , —CH claim 1 , —OH claim 1 , —OCH claim 1 , —C(═O)NH claim 1 , —NH—CO—CH claim 1 , —NH—SO—CH claim 1 , —NH—SO—CH—CH claim 1 , —NH—SO—CH(CH)—CH claim 1 , —NH—SO—(CH) claim 1 , —NH—SO—(CH)—CN claim 1 , —NHSOCF claim 1 , or —S(═O)NHCH.2328-. (canceled)30. The compound of wherein E is —S— or —X═X—.3137-. (canceled)38. The compound of wherein (G) is an aryl or heterocyclyl.3941-. (canceled)42. The compound of wherein each (R1) is independently chosen from alkyl claim 29 , aryl claim 29 , amino claim 29 , amido claim 29 , nitro claim 29 , halo claim 29 , haloalkyl claim 29 , cyano claim 29 , heterocyclyl claim 29 , sulfonyl claim 29 , sulfonamide claim 29 , hydroxyl claim 29 , or alkoxy.4446-. (canceled)47. The compound of wherein (G) is an aryl or heterocyclyl.4850-. (canceled)51. The compound of wherein each (R1) is independently chosen from alkyl claim 43 , aryl ...

Подробнее
01-08-2013 дата публикации

USE OF THE FETAL REPROGRAMMING OF A PPAR AGONIST

Номер: US20130197043A1
Принадлежит: SNU R&DB FOUNDATION

Disclosed is a novel use of a PPAR δ agonist, and more particularly, a fetal reprogramming effect of a PPAR δ agonist. A PPAR δ agonist adjusts calcium ion during embryo genesis and a early fetal development period to increase slow muscle fiber and to thus improve muscle endurance, thereby improving lipid and glucose metabolism and reprogramming the metabolism of the entire body, thus preventing/inhibiting the occurrence of metabolic diseases, such as obesity and diabetes in an adult body caused by a high-fat diet and a lack of exercise, and improving memory for an adult. 1. A composition for fetal reprogramming of a mammal , the composition containing a peroxisome proliferator activated receptor δ (PPAR δ) agonist as an effective component.2. The composition of claim 1 , wherein the composition enhances muscle endurance claim 1 , prevents metabolic diseases claim 1 , or improves memory of an object born or produced by a fetal reprogramming method.3. The composition of claim 2 , wherein the metabolic diseases are obesity claim 2 , diabetes claim 2 , hyperlipidemia claim 2 , arteriosclerosis claim 2 , or fatty acid.4. The composition of claim 1 , wherein the composition increases a birthrate of descendants or offspring claim 1 , improves tolerance to illness claim 1 , or lengthens lifespan.5. The composition of claim 1 , wherein the mammal is a human being.6. The composition of claim 1 , wherein the mammal excludes a human being.7. The composition of claim 1 , wherein the composition is administered to a mother body claim 1 , or descendants or offspring thereof during a gestation period claim 1 , a lactation period claim 1 , or gestation and lactation periods.18. A composition for medicine for treating and preventing atherosclerosis or hyperlipidemia claim 15 , treating and preventing hypercholesterolemia claim 15 , treating and preventing fatty liver claim 15 , treating and preventing diabetes claim 15 , treating and preventing obesity claim 15 , strengthening ...

Подробнее